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ABSTRACT 
Neural progenitor cells (NPCs) are present in the developing and adult neuroepithelium of the brain 
and are regulated by internal and external signals that influence neurogenesis and tissue homeostasis. 
NPCs are multipotent tissue stem cells that can arouse all neural cell types, including neurons and glial 
cells. In culture, NPCs grow preferentially as cell aggregates called neurospheres. This suggests that 
interactions between cells are essential to regulate NPC behavior and development. Interactions 
between cells may be facilitated by cell surface-attached proteases and their inhibitors that play an 
important role in development and during tissue remodeling after injury. Thus, they could regulate also 
brain development. 
Neuroinflammation, an innate immune response of the nervous system, is part of many 
neurodegenerative diseases. Neuroinflammation involves activation of microglia and production of 
proinflammatory cytokines. During neuroinflammation, NPCs interact with the immune system and 
may decrease inflammatory effects in the brain. However, inflammation may have negative effects on 
NPCs and thus, agents that protect NPCs could serve as a therapeutic potential for neuronal injuries 
and neurodegenerative diseases by enabling local tissue repair in the brain. 
The aim of this thesis was to study the regulation of NPC development by membrane-associated 
proteins and the effects of inflammation on NPCs. Glucocorticoid hormone (GH) levels increase in 
inflammation and after stress. GHs have previously been shown to decrease NPC proliferation and 
neurogenesis. We have studied the effects of a synthetic GH dexamethasone on the cytosolic 
membrane-associated and anti-apoptotic protein BRUCE, and how BRUCE affects NPC behaviour. In 
addition, we have studied the secretion of cytokine interferon-gamma (IFN) after microglial activation 
and further the influence of IFN on NPCs. To address the role of cell surface-associated protease 
inhibitors during NPC development, we have studied the expression and function of Kunitz type serine 
protease inhibitors hepatocyte growth factor activator inhibitors -1 (HAI-1) and -2 (HAI-2) in NPCs. 
The results show that dexamethasone enhances degradation of BRUCE by the ubiquitin-proteasome 
system (UPS), which leads to decreased NPC proliferation. NPC division was negatively affected also 
by IFN produced by microglial cells as well as protease inhibitors HAI-1 and HAI-2. Moreover, IFN 
induced NPC cell death that was rescued by a neuropeptide pituitary adenylate cyclase-activating 
peptide (PACAP). In the developing NPCs, HAI-1 and HAI-2 expression was increased by bone 
morphogenetic protein-2 (BMP-2) and BMP-4, which inhibited NPC proliferation and increased glial 
cell differentiation partly in a HAI-dependent manner. 
This thesis provides knowledge about interplay between immune cells and NPCs as well as 
developmental signaling systems, including proteolytic pathways, that affect NPC behaviour. In NPCs, 
proteolytic pathways may be regulated by external signals, like cytokines, from the neighboring cells. 
Proteolysis is involved also in the UPS that regulates the cell cycle machinery and thus, cell division. 
This thesis also deals with NPC survival, which is of importance for stem cell therapies. Knowledge of 
reciprocal effects of IFN and PACAP on NPCs is relevant when designing treatment for brain 
inflammation and disease. 
 
 
  
TIIVISTELMÄ (Abstract in Finnish) 
Aivojen kehityksen aikana lukuisat viestintäreitit solujen välillä sekä solun sisällä säätelevät hermoston 
kantasoluja. Hermoston kantasolut ovat niin kutsuttuja kudoskantasoluja, joilla on kyky uusiutua. Ne 
voivat myös erilaistua hermoston eri solutyypeiksi, kuten hermosoluiksi ja hermotukisoluiksi. 
Hermoston kantasolujen sijainti aivoissa vaikuttaa niiden kehittymiseen ja ne jakautuvat usein vain 
tietyssä mikroympäristössä, joka säätelee niiden erilaistumista. Viljelmässä hermoston kantasolut 
kasvavat aggregaatteina, mikä tukee niiden kasvua ja jakautumista viitaten solujen välisten 
vuorovaikutusten olevan tärkeitä niiden kehitykselle. Solujen välisiä kontakteja sekä vuorovaikutusta 
ulkoisen ympäristön kanssa voivat välittää solun pinnalla sijaitsevat proteiineja pilkkovat proteaasit sekä 
niiden estäjät, joilla on tärkeä rooli jo sikiönkehityksen aikana sekä kudosten uusiutumisessa. 
Tulehdus on läsnä monissa hermoston tautitiloissa ja sen on näytetty vaikuttavan negatiivisesti 
hermoston kantasoluihin ja hermosolujen syntymiseen. Aivojen tulehdusreaktioissa mikroglia-solut 
aktivoituvat ja erittävät tulehdusta edistäviä tulehdusvälittäjäaineita, kuten sytokiinejä, jotka välittävät 
elimistön immuunijärjestelmän vuorovaikutuksia. Hermoston kantasolut voivat olla vuorovaikutuksessa 
immuunijärjestelmän kanssa ja saattavat vähentää aivojen tulehdusvastetta. Aivojen tulehdusreaktioissa 
ja erityisesti aivovaurioissa molekyylejä, jotka suojelevat hermoston kantasoluja, voitaisiin käyttää 
vaurion hoidossa lisäämään tuhoutuneen kudoksen uusiutumispotentiaalia. 
Väitöskirja tutkii hermoston kantasolujen jakautumista ja erilaistumista sekä sitä, miten eri tekijät, kuten 
sytokiinit ja solukalvoilla sijaitsevat proteiinit vaikuttavat näiden solujen kehittymiseen sekä niiden 
säätelyyn aivojen tulehdusreaktioissa. Glukokortikoidihormonit ovat osa elimistön immuunijärjestelmän 
mekanismia, joka vähentää tulehdusvastetta. Niiden määrä lisääntyy stressin tai immuunivasteen 
seurauksena ja niiden on näytetty vähentävän hermoston kantasolujen jakautumista ja hermosolujen 
syntymistä. Väitöskirjassa on selvitetty synteettisen glukokortikoidihormoni deksametasonin vaikutusta 
hermoston kantasolujen ilmentämään BRUCE-proteiiniin sekä sitä, kuinka BRUCE säätelee 
kantasoluja. Lisäksi väitöskirjassa on tutkittu tulehdusreaktioissa erittyvän sytokiini interferoni-gamman 
vaikutusta hermoston kantasoluihin sekä solukalvolla sijaitsevien proteaasiestäjien HAI-1 ja HAI-2 
ilmentymistä ja toimintaa näissä soluissa. 
Deksametasonin osoitettiin lisäävän hermoston kantasoluja säätelevän BRUCE-proteiinin hajotusta 
proteasomissa, mikä vähensi solujen jakautumista. Myös interferoni-gamma, jota erittyi aivojen 
mikroglia-soluista, sekä HAI-1 ja HAI-2 vähensivät hermoston kantasolujen jakautumista. Interferoni-
gamma myös lisäsi hermoston kantasolujen solukuolemaa, joka kuitenkin estyi suojaavan PACAP-
neuropeptidin vaikutuksesta. BMP-sytokiinien BMP2 ja BMP4 osoitettiin lisäävän HAI-
proteaasiestäjien ilmentymistä hermoston kantasoluissa. Lisäksi ne vähensivät kantasolujen jakautumista 
ja lisäsivät niiden erilaistumista hermotukisoluiksi, astrosyyteiksi, osittain HAI-proteiinien välityksellä. 
Väitöskirjatyö osoittaa, että hermoston kantasolujen pinnalla esiintyvät proteaasiestäjät säätelevät 
solujen käyttäytymistä ohjaten niiden kehitystä ja kohtaloa aivojen kehityksen aikana. Lisäksi 
proteasomihajotuksella on rooli hermoston kantasolujen jakautumisen säätelyssä. Väitöskirja myös 
osoittaa aivojen mikroglia-solujen vaikuttavan sytokiinien välityksellä hermoston kantasoluihin. 
Hermoston kantasolut ovat herkkiä tulehdusvälittäjäaineille, ja niiden jakautuminen voi häiriintyä 
hermoston tautitiloissa ja aivovaurion seurauksena. Siksi niiden kasvun ja jakautumisen säätely on 
tärkeää etenkin stressi- ja tulehdusreaktioissa ja myös suunniteltaessa kantasoluterapiaa. 
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1 INTRODUCTION 
The brain development results from series of cellular events, including proliferation, differentiation, 
migration and cell death of neural stem/progenitor cells (NSC/NPC). These cells are multipotent stem 
cells with restricted differentiation potential only into neurons and glial cells. NSCs/NPCs are regulated 
during the brain development by extrinsic and intrinsic signals to guide the proper formation of the 
complex hierarchy of brain structures. Signals from the cell surroundings are transferred inside the cell 
to activate intracellular signaling pathways that regulate the cell phenotype and fate. In addition, cell-to-
cell signaling via plasma membrane contact may influence cell behavior. NPCs may interact with other 
brain cells or with each other through proteins expressed on the cell membrane. Moreover, they are 
affected by secreted factors from other cells. 
NSCs are present also in the adult brain, most prominently in the subventricular zone of lateral 
ventricles and in the dentate gyrus (DG) of hippocampus (Decimo et al., 2012). Adult NSCs serve as a 
reservoir for cell differentiation and replacement, and endogenous progenitors are valuable in situations 
of tissue damage that may occur in brain trauma or in neurodegenerative diseases. However, 
neurogenesis in the brain is affected by various cues, including trophic factors, cytokines and drug 
treatments, and in several physio- and pathological conditions. Stress is associated with a transient 
reduction in DG neurogenesis (Decimo et al., 2012). In neurological diseases and disorders, including 
Alzheimer´s disease, epilepsy, Huntington´s disease and Parkinson´s disease, neurogenesis is often 
upregulated in the lesioned brain (Taupin 2008). Hence, the stimulation of endogenous NPCs to 
control neurogenesis could contribute to regeneration of the injured or diseased brain.  
Tissue injury in the brain often activates brain immune function that may be noxious for the healthy 
tissue. Neuroinflammation is involved in the pathogenesis of brain diseases and disorders (Raison et al., 
2006; Qian et al., 2010). It affects also NPCs and decreases neurogenesis but, on the other hand, NPCs 
may promote neuroprotection by modulating the immune reaction (Taupin 2008). Stress can affect 
immune function by alterations in hormone levels, and chronic stress may also result in brain 
pathogenesis (Bilbo and Schwarz, 2012). 
In order to protect NPCs from harmful effects of inflammation, it is important to study, how NPCs 
are affected by neuroinflammation and how their survival can be enhanced. Since NPCs in the brain 
may not tolerate the effects of inflammatory challenge, it is also worth to explore the regenerative 
capacity of these cells for stem cell therapies. In the case of injury, endogenous NPCs or 
transplantation of stem cells into the brain may decrease inflammation, restrict cell death through 
neurotrophic effects and enhance endogenous cell proliferation and recovery processes (Christie and 
Turnley, 2012; Giusto et al., 2013). Thus, a proper knowledge of the regulation of NPCs is essential for 
the development of cell therapies and therapeutic agents. 
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The mammalian brain is developed from the neuroepithelial lining of the neural tube that is of 
ectodermal origin. During early development, neuroepithelial (NE) cells that are the primary neural 
stem cells (NSCs) first undergo symmetrical cell divisions to produce more neuroepithelial cells and to 
form the thickening germinal layer, called the ventricular zone (VZ) (Smart, 1972). Later, they switch to 
asymmetric mode of division generating more restricted neural progenitor cells, including radial glial 
cells (RGCs) and intermediate progenitor cells (IPCs; also called basal progenitors) (Figure 1)(Chenn 
and McConnell, 1995; Huttner and Brand, 1997). With the onset of neurogenesis and following the 
neural tube closure, neuroepithelial cells transform into RGCs that continue cell divisions 
asymmetrically. By these self-renewing divisions, RGCs produce two daughter cells: a daughter cell of a 
same kind and a daughter cell that exhibits an IP- or a neuron-type character (Haubensak et al., 2004; 
Miyata et al., 2004; Noctor et al., 2004; 2007). Thus, through IPCs, RGCs are capable of producing 
neurons also indirectly. Moreover, RGC-derived IPCs may also generate oligodendrocytes. IPCs divide 
symmetrically to produce two neurons or two oligodendrocytes depending on the cell fate (Haubensak 
et al., 2004; Noctor et al., 2004; 2008; Attardo et al., 2008). In addition, a minority of IPCs is able to 
undergo proliferating symmetric division to expand the progenitor pool (Attardo et al., 2008; Noctor et 
al., 2008). Thus, IPCs form another proliferating layer near the ventricle, the subventricular zone 
(SVZ). Finally, at the end of embryonic development, majority of RGCs lose their apical attachment 
and convert into astrocytes (Schmechel and Rakic, 1979; Noctor et al., 2008). Some of the RGCs 
remain as a ventricular stem cell population in the adult brain (Kriegstein and Alvarez-Buylla, 2009). 
During the development, RGCs also serve as a scaffold for the formation of cortical layers in the brain 
by guiding the migration of newborn neurons to reach the cortical plate (Rakic, 1971; 1972). Immature 
neurons migrate along the radial fibers and differentiate into pyramidal cells of the cortex (Gadisseux et 
al., 1990; Marín-Padilla, 1992). 
                                  
Figure 1. Lineage relationships of neural stem/progenitor cells and their progeny. Neuroepithelial (NE) cells convert into radial glial cells (RGCs) that give rise to intermediate progenitor cells (IPCs) and neurons. During the late embryogenesis RGCs transform into astrocytes. IPCs produce neurons and oligodendrocytes. Cell type-specific markers for stem cells and progenitors are shown in italics. DCX, doublecortin; GFAP, glial fibrillary acidic protein; MAP2, microtubule-associated protein 2; Tbr2, T-brain gene-2. 
2 REVIEW OF THE LITERATURE 
2.1 Brain stem cell development 
   
3 REVIEW OF THE LITERATURE 
2.1.1 Neural stem/progenitor cells 
Neuroepithelial cells are anchored to each other by tight junctions (Aaku-Saraste et al., 1996) and form 
a specialized epithelium that lines the lumen of the cerebral ventricles early in embryonic development. 
NE cells give rise to all neurons in the mammalian neocortex. They are polarized cells extending from 
the apical surface of the ventricle into the basal/pial surface to contact the basal lamina (Huttner and 
Brand, 1997). They go through mitotic divisions at the ventricular surface but their nuclei migrate 
within the cytoplasm in a manner of interkinetic nuclear migration (INM) (Sauer and Walker, 1959). 
During DNA synthesis (S) phase, nuclei form a layer above the VZ while nuclei in gap phases 1 (G1) 
and 2 (G2) travel between these layers in apical-to-basal and basal-to-apical direction, respectively. 
Neuroepithelial cells are characterized by the expression of transcription factors Sox1, -2 and -3 
(Bylund et al., 2003). In addition, they share the expression of RC1 and RC2 epitopes with RGCs 
(Misson et al., 1988a; Edwards et al., 1990). At the beginning of cortical neurogenesis, NE cells begin to 
show radial glial cell characteristics. 
RGCs are bipolar cells that share some features with neuroepithelial cells, like apical-basal polarity and 
contacts with both pial and ventricular surfaces through a radial process. They also undergo INM but 
their nuclei migrate only within the VZ (Misson et al., 1988b). RGCs, however, acquire morphological 
changes as well as changes in the expression of intermediate filament proteins and transcription factors. 
RGCs are connected to each other by adherens junctions and they obtain 24-nm microtubules and 9-
nm intermediate filaments accompanied by the growth of the radial fiber (Choi and Lapham, 1978). 
They also contain glycogen storage granules near the basal end feet (Brückner and Biesold, 1981). 
RGCs permeate the entire cortical wall and guide the migration of newborn neuroblasts. In contrast to 
NE cells, RGCs start to elongate their glial processes, which precedes glial transformation (Takahashi et 
al., 1990). 
RGCs are distinguished from neuroepithelial cells by the expression of astroglial markers, including 
glutamate aspartate transporter (GLAST), brain lipid-binding protein (BLBP), nestin and vimentin 
(Schnitzer et al., 1981; Tohyama et al., 1992; Feng et al., 1994; Shibata et al., 1997; Perez-Alvarez et al., 
2008). Later, they also start to express the astroglial intermediate filament protein glial fibrillary acidic 
protein (GFAP). In addition, RGCs are characterized by expression of a transcription factor Pax6, 
which is required for RGC identity and their neuronal differentiation (Götz et al., 1998; Heins et al., 
2002; Haubst et al., 2004). RGCs also show high Sox2 expression that declines during the 
differentiation (Hutton and Pevny, 2011). The maintenance of RGCs is mediated by Notch signaling 
that inhibits the activation of proneural genes (Gaiano et al., 2000). 
Intermediate progenitor cells appear in the VZ as a result of RGC division. IPCs retract from the 
ventricular surface to populate the second germinal layer of the neuroepithelium, the SVZ (Miyata et 
al., 2004). They lose adherent junctions and lack INM but undergo apical-to-basal translocation within 
the basal VZ and the SVZ to perform cell division (Farkas and Huttner, 2008). Contrary to NE cells 
and RGCs that perform cell division in a vertical orientation (perpendicular to the apical surface), IPCs 
acquire a horizontal (parallel) cleavage plain orientation (Noctor et al., 2008). IPCs have a restricted 
2.1.1.1  Neuroepithelial cells 
2.1.1.2  Radial glial cells 
2.1.1.3  Intermediate progenitor cells 
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potential to differentiate only to a neuronal or glial cell type. Maintenance of IPCs is dependent on 
interactions with other cells in the developing neuroepithelium. IPCs are identified by T-brain gene-2 
(Tbr2) expression, which is required for IPC specification (Sessa et al., 2008; Englund et al., 2005). 
2.1.2 Stem cell niche 
Stem cells in adult tissues are found in a specific microenvironment called a stem cell niche. The niche 
supports the survival and renewal of stem cells and regulates their proliferation and differentiation 
potential by cell signaling of secreted paracrine factors as well as by cell interactions with other cells and 
with the extracellular matrix. Regulation of stem cell niche is of importance to preserve the stem cell 
pool and to enable continuous stem cell division for tissue maintenance and its regeneration after 
injury. 
Neural stem cells reside in specific areas in the adult brain, from which the most familiar are the 
subgranular zone of dentate gyrus in hippocampus and a subependymal zone of the lateral ventricles 
(reviewed in Kriegstein and Alvarez-Buylla, 2009). In adult hippocampus, neurogenesis occurs locally 
while the SVZ progenitors migrate along the rostral migratory stream to the olfactory bulb to replace 
interneurons (Imayoshi et al., 2008). However, neurogenesis have been detected also in other locations 
in the adult brain, including substantia nigra, amygdala, striatum and neocortex (Gould et al., 1999; 
Bernier et al., 2002; Zhao et al., 2003). Signaling in the neurogenic stem cell niche is mediated by 
different cell types residing in the niche, including NSCs, ependymal cells, blood vessel cells and glial 
cells. Recently, also embryonic neural stem cells have been considered to be regulated by niche-like 
signals by their neighboring cells, including neuroblasts, endothelial cells and RGCs (Shen et al., 2004; 
Gama Sosa et al., 2007; Yoon et al., 2008; Nishikawa et al., 2010). Niche-promoting signals may be 
facilitated via both extrinsic and intrinsic cues. The cerebrospinal fluid provides signals that promote 
cortical progenitor cell proliferation by contacting the apical domain in the VZ (Lehtinen et al., 2011). 
In addition, extracellular matrix protein tenascin C has been shown to provide support for neural stem 
cell development by regulating growth factor signaling (Garcion et al., 2004). Signaling between cells 
may be facilitated through gap junctions, which form channels with an aqueous pore between the 
adjacent cells and allow exchange of small molecules, ions and electrical current. RGC division is 
regulated by gap junction-mediated cell coupling and waves of calcium ions (Lo Turco and Kriegstein, 
1991; Bittman et al., 1997; Weissman et al., 2004). Cell-to-cell signaling may also occur through direct 
cell contact between different cell types (Tung and Lee, 2012). 
2.1.3 Proliferation and self-renewal 
The purpose of cell proliferation is the self-renewal of a cell to produce similar progeny and to expand 
the cell population. In the context of neural stem/progenitor cells, proliferation is also required for 
generation of downstream progenitor cells as well as neurons. 
Cell division is required for growth, development and tissue renewal. Mitotic cell division involves the 
distribution of identical genetic material into two daughter cells by means of DNA replication, after 
which the actual cell division takes place. The mitotic cell division is divided into mitosis and 
cytokinesis. Mitosis divides the nuclear material into daughter nuclei, and cytokinesis divides the 
cytoplasm and the plasma membrane, generating two daughter cells. During mitosis, the mitotic spindle 
2.1.3.1 Cell division 
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guides the replicated chromosomes into the opposite poles of the cell and the daughter nuclei re-form 
around them. 
Cytokinesis begins during the last stage of mitosis with the appearance of a cleavage furrow, a groove at 
the cell surface that determines the cleavage plane (Eggert et al., 2006). The place and ingression of the 
cleavage furrow is determined in a consecutive manner by microtubule asters and the mitotic spindle 
midzone (Bringmann and Hyman, 2005). The cleavage furrow is deepened by the contraction of a 
contractile ring made of actin filaments associated with myosin proteins that assemble on the 
cytoplasmic side of the furrow (Tucker, 1971). Assemble of the contractile ring is facilitated by the 
small GTPase RhoA via activation of its downstream effector proteins (Piekny et al., 2005). Before 
cleavage, the daughter cells are connected to each other by an intercellular bridge containing a midbody 
ring made of antiparallel microtubule bundles. In the last step of cytokinesis, abscission, the 
cytoplasmic connection is closed between the daughter cells via membrane fusion. 
A daughter cell fate of a neural stem cell is defined by a cleavage plane orientation and the symmetry of 
cell division. The symmetric division produces two identical daughter cells, whereas the asymmetric 
division generates two daughter cells with different fate. Neural stem cell division may be a symmetric 
proliferative, a symmetric differentiative, an asymmetric self-renewing or an asymmetric differentiative 
division (Figure 2). 
 
                                 
 
Figure 2. Cell division in neural stem cells. An asymmetric division (above) produces daughter cells with different fates and is either a self-renewing or a differentiative division yielding a similar stem cell and a differentiated cell or two daughter cells that further differentiate, respectively. A symmetric cell division in NSCs (below) generates identical progeny including either proliferative progenitors or differentiating cells. IPC, intermediate progenitor cell; RGC, radial glial cell. 
A vertical cleavage occurs perpendicular to the apical surface of the ventricular zone and results in 
symmetric or asymmetric division of a neural progenitor cell, while a horizontal cleavage plane divides 
the cell parallel to the apical surface resulting in asymmetric division (Chenn and McConnell, 1995; 
Kosodo et al., 2004). The fate of a vertically dividing cell depends on whether the apical plasma 
membrane is bisected or bypassed and thus, whether the apical membrane domain is equally or 
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unequally distributed to the daughter cell (Kosodo et al., 2004) (Figure 3). Symmetric vs. asymmetric 
division is known to be regulated by Notch inhibitors Numb and Numblike, whose inactivation 
increases symmetric proliferative divisions and the progenitor cell number in the developing mouse 
forebrain (Li et al., 2003). Furthermore, Notch activation in the mammalian cerebral cortex progenitors 
leads to increased proliferative divisions (Mizutani and Saito, 2005). Recent data indicates a role for a 
transcription factor Pax6 in regulating the orientation of cell division as loss of Pax6 results in increased 
asymmetric vertical cleavage and an increase in basal progenitor divisions (Asami et al., 2011). The 
apical-basal polarity of neural progenitors is also essential for the proper symmetry of cell division. 
Mice lacking the mammalian homologue of the Drosophila lethal giant larvae gene, Lgl1, show 
hyperproliferation of neural progenitors due to disrupted cell polarity and a failure of asymmetric cell 
divisions (Klezovitch et al., 2004). Moreover, the loss of apical-basal polarity in intermediate progenitor 
cells allows only symmetric cell division (Attardo et al., 2008). 
                                              
Figure 3. Symmetric and asymmetric cell division in neural stem cells with vertical cleavage plane 
orientation. On the left, symmetric division with orientation of the mitotic spindle perpendicular to the apical surface results in equal distribution of the apical plasma membrane. On the right, asymmetric division with tilted orientation of the mitotic spindle results in unequal segmentation of the apical plasma membrane. Modified from 
Huttner and Kosodo, 2005. 
In the mitotic cell cycle, the mitotic (M) phase alternates with interphase. Interphase comprises gap 
phases G1 and G2 as well as DNA synthesis (S) phase. In addition, G0 phase comprises a resting phase 
for a cell that exits the cell cycle from G1 phase. Terminally differentiated cells, like neurons, are 
permanently in this quiescent state and never enter the cell cycle again. During gap phases G1 and G2, 
the cell grows and produces more cytoplasm as well as generates new proteins and organelles. In the S 
phase, a cell duplicates its chromosomes. 
The cell cycle is regulated by cell-cycle checkpoints and the cell-cycle clock, the latter of which involves 
cyclins and cyclin-dependent kinases (Cdks) (Figure 4). In G1 phase, Cdk4/6-cyclin D and Cdk2-
cyclin E complexes, required for progression through G1, sequentially phosphorylate and inhibit the 
retinoblastoma protein (Rb) enabling entry into the S phase (Lundberg and Weinberg, 1998; Harbour et 
al., 1999). Cdk2 then interacts with cyclin A to complete the S phase, after which cyclin A binds Cdk1. 
This complex runs the cell through G2 phase and then dissociates for Cdk1 to associate with cyclin B, 
which is required for G2-M transition and initiation of mitosis (Gavet and Pines, 2010). 
DNA damage and spindle assembly checkpoints at G1, G2 and M phases determine whether the cell is 
ready to move forward in the cell cycle (Elledge, 1996). The cell cycle is halted at the checkpoint by 
stop signals until essential cellular processes are completed for cell to proceed. Concentration and 
activity of cyclin-cdk complexes are essential to control the entry into the next cell cycle phase. 
2.1.3.2 Cell cycle  
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Figure 4. The cell cycle. Cyclin D-cdk4/6 and Cyclin E-cdk2 complexes are involved in G1 phase to sequentially phosphorylate the retinoblastoma protein (Rb) that leads to its inactivation and entry into S phase. In S phase, Cdk2 forms a complex with Cyclin A that drives the cell to the next phase. Progression through G2 phase is facilitated by Cyclin A-cdk1 complex and finally, Cyclin B-cdk1 complex mediates the G2/M transition. After mitosis, the cell may exit the cell cycle into the resting phase, G0. Cell cycle checkpoints at G1, G2 and M phases control cell cycle progression by monitoring proper DNA replication and spindle formation. 
Cdks are activated by an association of a cyclin subunit and further by phosphorylation by Cdk-
activating kinase. In addition, they are regulated through inhibition by Cdk-inhibitors (CKIs) that are 
members of the Ink4 or Cip/Kip families. The p53Kip2 protein coded by p53 tumor suppressor gene is a 
negative regulator of the cell cycle that is induced by DNA damage. p53 Kip2 protein activates p21Cip1 
expression that is able to block cyclin-cdk complexes and halt the cell cycle. p53 Kip2 protein has been 
shown to affect neural stem/progenitor cell self-renewal (Meletis et al., 2006; Piltti et al., 2006). 
However, it is best known for its ability to induce apoptosis (reviewed in Miller et al., 2000). Another 
tumor suppressor, the retinoblastoma protein Rb inhibits DNA synthesis and induces cell cycle exit. It 
is involved in the cell cycle machinery of NPCs as it was shown to decrease their proliferative capacity 
(Piltti et al., 2006). Moreover, a proto-oncogene c-myc regulates the cell cycle but has various roles in 
different cell types and tissues (Grandori et al., 2000; Murphy et al., 2005). It is a transcription factor 
that affects transcription through several mechanisms (Grandori et al., 2000). It has been shown to 
increase NPC self-renewal through its ability to bind Myc-interacting zinc finger protein-1 (Miz-1), an 
inhibitor of CKIs (Kerosuo et al., 2008). 
Cyclin D1 belonging to D type cyclins, controls the cell cycle progression in G1 phase (Baldin et al., 
1993). Cyclin D1 expression is induced by growth factors and thus, it acts as a sensor for extracellular 
signals to mediate cell proliferation but also differentiation, migration and tumorigenesis that are 
regulated independently of the cell cycle machinery (Fu et al., 2004). It is essential also in regulation of 
NPC proliferation (Sundberg et al., 2006). 
 
2.1.3.3 Cell cycle regulators 
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2.1.4 Neuronal and glial development 
The generation of neurons from neural stem/progenitor cells, or neurogenesis, is regulated by so called 
proneural genes constituting of basic helix-loop-helix (bHLH) transcription factors (Figure 5). These 
factors have been grouped to distinct families based on similarities in the bHLH domain sequence. In 
the mouse, only a few genes possess true proneural activity to facilitate progenitor commitment, 
including Mash1, Neurogenins 1-3 (Ngn1-3), Math1 and Math5 (Ma et al., 1996; Sommer et al., 1995; 
1996; Lee 1997; Farah et al., 2000). In addition, the NeuroD and Olig family members share a bHLH 
domain structure, and are involved in further neuronal differentiation (Lee et al., 1995; Sommer et al., 
1996; Farah et al., 2000; Takebayashi et al., 2000). 
Proneural genes are expressed already in NE cell stage, where they are induced by neurogenic signals, 
such as bone morphogenetic protein 2 (BMP2), platelet-derived growth factor (PDGF) and 
erythropoietin (Johe et al., 1996; Lo et al., 1997; Williams et al., 1997; Shingo et al., 2001). Activated 
proneural genes regulate neural fate specification and promote progenitor development into neuronal 
lineages. Proneural genes are negatively regulated by repressor-type HLH factor families Hes 
(mammalian homologue of Hairy and Enhancer of Split) and Id (inhibitor of differentiation) that have 
changed or lacking DNA binding ability compared to bHLH proteins (Benezra et al., 1990; Sun et al., 
1991; Akazawa et al., 1992; Sasai et al., 1992). Proneural activity is facilitated through Notch signaling 
by a mechanism of lateral inhibition. Proneural genes prevent their own expression by Notch ligands 
that activate Notch and upregulate Hes-1 and Hes-5 in neighboring cells, which stay undifferentiated 
(Kageyama et al., 2005). After Notch-induced upregulation of bHLH genes, their expression is 
maintained by positive feedback mechanisms of activated downstream genes that facilitate neuronal 
differentiation. Proneural genes also inhibit glial specifiers and promote cell cycle exit. Moreover, 
different proneural genes are responsible for the specification of particular neuronal subtypes. 
In the murine brain, switch from neurogenesis to gliogenesis occurs at the end of embryonic 
development and is induced by downregulation of proneural genes (Figure 5). Astrocytogenesis is 
initiated by gliogenic signals, including ciliary neurotrophic factor, fibroblast growth factor, interleukin-
6 (IL-6), leukemia inhibitory factor (LIF) and BMPs (Johe et al., 1996; Bonni et al., 1997; Rajan and 
McKay, 1998; Nakashima et al., 1999; Islam et al., 2009). These gliogenic signals activate the Janus 
tyrosine kinase/signal transducers and activators of transcription (JAK/STAT) pathway. 
Phosphorylated STAT transcription factors form a complex with the transcriptional co-activators 
CREB binding protein (CBP)/p300 onto astrocytic promoters to induce expression of astrocyte-
specific genes, like GFAP. The dual role of BMPs in the regulation of both neurogenesis and 
gliogenesis is explained by competition between Ngn1 and STAT for CBP/p300 association and 
joining of BMP effector Smad into this complex. During early cortical development, Ngn1 inhibits 
STAT phosphorylation and combine to CBP/p300 preventing glial gene expression and promoting 
neuronal gene transcription (Sun et al., 2001). STAT is able to induce expression of negative HLH 
transcription factors Id2, Id3 and Hes-5 (Gu et al., 2005) leading to reduced proneural gene expression. 
In addition, BMP2 induces the expression of inhibitory HLH proteins Id1, Id2 and Hes-5 through 
Smad signaling (Nakashima et al., 2001). Astroglial fate is also regulated by Notch signaling. Inhibitory 
bHLH factors, Hes1 and Hes5, as well as STAT3 have been shown to be targets of Notch activation 
(Kamakura et al., 2004) that inhibits neurogenesis and oligodendroglial differentiation and promotes 
astroglial cell fate (Wang et al., 1998; Tanigaki et al., 2001). 
Oligodendrocyte fate determination is regulated by sonic hedgehog (Shh), which upregulates 
oligodendrocytic markers O4 and chondroitin sulfate proteoglycan NG2 as well as bHLH factors Olig1 
and Olig2 that promote oligodendroglial cell identity (Lu et al., 2000; Zhou et al., 2000; Alberta et al., 
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2001). However, Olig1 and Olig2 are also involved in motor neuron specification during early 
development, due to cooperation with Ngn2. Downregulation of Ngn2 and expression of Nkx2.2 in 
progenitor cells serves as a switch from neuronal differentiation to oligodendrocyte development 
(Zhou et al., 2001b). 
 
Figure 5. Timeline of neuronal and glial development in rat. During early embryogenesis, neural stem cells produce neurons as a consequence of neurogenic signals that induce proneural gene expression and subsequently inhibit glial differentiation. At the same time, lateral inhibition prevents proneural gene expression in other cells that do not enter the neuronal pathway. The switch from neurogenesis to gliogenesis occurs through gliogenic signals that activate glial differentiation and, in parallel, inhibit neuronal differentiation. In rats, neurogenesis peaks at E14, astrocytogenesis at P2 and oligodendrocytogenesis at P14. E, embryonic day; P, postnatal day. Modified from Bertrand et al., 2002. 
2.1.5 Cell death 
Cell death is traditionally divided into necrosis and apoptosis that were originally distinquished by Kerr 
et al. (1972). However, recently also other ways of cell death have been described, including oncosis 
and necroptosis. Apoptosis and oncosis are processes that lead to cell death, while necrosis is an 
unregulated condition appearing after cell death. Oncosis, or ischemic cell death, is characterized by an 
apparent cellular swelling that leads to disappearance of the nucleus, while apoptosis exhibits cellular 
shrinking resulting in nuclear fragmentation (Majno and Joris, 1995). Necrosis is recognized by 
morphological changes, such as cellular swelling and chromatin condensation that results in cell lysis 
and inflammation (Wyllie et al., 1980). On the other hand, necroptosis is a regulated form of necrosis 
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that shares the same morphological features (Degterev et al., 2005; Cho et al., 2009; He et al., 2009; 
Zhang et al., 2009).  
Apoptosis, or programmed cell death, differs from other cell death mechanisms as being a genetically 
regulated cellular suicide. It is required in maintaining tissue and cellular homeostasis and to control 
balance between cell proliferation and cell death. Apoptosis can be triggered by several extrinsic and 
intrinsic mechanisms, which lead to activation of the suicide program. Also lack of signals, like 
neurotrophin deprivation during neural development, or environmental cues may induce apoptosis. 
During the development, neural progenitor cells die through apoptosis, which regulates the number of 
progenitors and eliminates the excess cells. NPCs undergo the so called proliferative apoptosis. NPC 
death is required for developmental processes, such as neural tube closure (Geelen and Langman, 
1977). In addition, proliferative apoptosis regulates the proper balance of proliferation and cell death 
within the neurogenic zone, as up to 70% of the developing cortical cells die during the embryogenesis 
(Blaschke et al., 1996; Thomaidou et al., 1997). Thus, apoptosis determines the size and shape of the 
brain. 
The cell morphological features of apoptosis include the nuclear fragmentation and the condensation 
of nuclear chromatin and cytoplasm into apoptotic bodies, as well as blebbing of the plasma membrane 
(Kerr et al., 1972). Apoptosis is regulated by the Bcl-2 (B cell lymphoma) family proteins, the adaptor 
protein Apoptosis protease activating factor (Apaf1) and caspase family of cysteine proteases. 
Mammalian Bcl-2 family includes both anti-apoptotic members, like Bcl-2 and Bcl-XL, that have 
multiple Bcl-2 homology domains (BH1-4), and pro-apoptotic members, which are divided into two 
categories by the presence of several BH domains (e.g. Bax) versus BH3 domain only (e.g. PUMA). 
Caspases are normally present as an inactive form, a procaspase. They are activated by a proteolytic 
cleavage that occurs during the caspase cascade, where activated upstream caspases cleave and activate 
downstream caspases. Mammalian upstream initiator caspases involved in apoptosis include caspases-2, 
-8, -9 and -10 that activate downstream effector caspases-3, -6, and -7 (Earnshaw et al., 1999). 
Apoptosis in NPCs follow either the mitochondrial or the death receptor pathway (De Zio et al., 2005). 
In the mitochondrial pathway the mitochondrial protein cytochrome c is released into the cytoplasm, 
where it binds Apaf1 and forms the apoptosome together with dATP, leading to the activation of 
caspase-9 (Li et al., 1997; Saleh et al., 1999). The death receptor pathway of apoptosis is induced by 
ligand binding to a cell membrane receptor that bears a cytoplasmic domain called a death domain 
(Boldin et al., 1995). Well-known death receptor ligands are Fas ligand and tumour necrosis factor α 
(TNFα) that activate Fas receptor and TNF receptor 1, respectively. Fas receptor binds procaspase-8 
via the death domain and forms a death-inducing signaling complex that subsequentially activates 
caspase-8 (Muzio et al., 1996; Medema et al., 1997). Both the mitochondrial and the death receptor 
pathway lead finally to the conversion of procaspase-3 into an active caspase-3 and the typical 
morphological features of apoptosis. 
2.1.5.1 Apoptosis 
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BMPs consist of more than 20 members in different species within transforming growth factor- 
(TGF-superfamily that also includes TGF-s, activins/inhibins, Lefty, Myostatin, anti-Müllerian 
hormone and growth-differentiation factors. BMPs were first discovered in the process of 
endochondral bone formation. BMP2, BMP4 and BMP6 relay glucocorticoid-induced differentiation of 
osteoblasts, BMP6 acting on earlier stage osteoprogenitor cells than BMP2 and BMP4 (Thies et al., 
1992; Rickard et al., 1994; Hughes et al., 1995; Boden et al., 1996; 1997). During the development, 
BMP members exhibit various spatiotemporal expression patterns. They regulate a diverse array of 
cellular processes, including proliferation, differentiation, cell lineage commitment, survival and 
apoptosis depending on the activated signaling cascade. BMPs regulate morphogenesis and 
differentiation in various developing organs, including kidneys, lungs, heart, teeth, skin and hair. BMPs 
are essential during early embryogenesis and are required for the formation of embryonic mesoderm 
and extraembryonic tissues as well as for the proper posterior patterning (Mishina et al., 1995; Winnier 
et al., 1995; Zhang and Bradley, 1996). Homozygous BMP2 mutant mice are embryonic lethal with 
defects in cardiac development (Zhang and Bradley, 1996). Lack of BMP7 attenuates kidney and eye 
development and interferes the accurate position of limbs (Dudley et al., 1995; Luo et al., 1995). BMP4 
is most prominent BMP family member that regulates tooth formation and differentiation (Neubüser et 
al., 1997; Zhang et al., 2000b; Gluhak-Heinrich et al., 2010). At the early embryogenesis, BMPs 
promote epidermal differentiation and inhibit neural induction from the embryonic ectoderm (Hawley 
et al., 1995; Wilson and Hemmati-Brivanlou, 1995). 
2.2.1 BMP signaling 
BMPs act as protein dimers and signal through tetramer complexes of specific serine/threonine kinase 
receptors, BMP receptors, on the cell membrane. BMP receptor (BMPR) complex contains two 
separate type II and type I receptors that together facilitate the signal transduction. There are different 
BMP type I receptors, of which most of the BMP members use ALK2 (activin receptor-like kinase 2), 
ALK3 (BMPR-IA) or ALK6 (BMPR-IB) (Table I). All BMPs activate BMP type II receptor BMPRII 
and may additionally bind to activin type II receptors ActR-II and ActR-IIB. Type II serine/threonine 
kinases are constantly active and upon ligand binding, they phosphorylate Gly-Ser domain in type I 
receptors leading to the activation of intracellular signaling cascade (Wrana et al., 1994). There exists 
also a co-receptor for BMPs, DRAGON, which potentiates BMP signaling by binding to BMP 
receptors or ligands (Samad et al., 2005). BMPs induce both Smad-dependent and Smad-independent 
signaling pathways (Figure 6) depending on the timing of receptor complex formation. Binding of a 
ligand to a preformed complex on the cell membrane activates Smad pathway, while ligand-induced 
receptor complex facilitates mitogen-activated protein kinase (MAPK) signaling pathways, including 
ERK (extracellular signal regulated kinase), JNK (c-Jun N-terminal kinase), p38 (MAP) kinase, as well 
as serine threonine kinase mTOR/FRAP (mammalian target of rapamycin/FKBP12-rapamycin-
associated protein) and LIM kinase 1 cascades (Yamaguchi et al., 1995; Shibuya et al., 1998; Lou et al., 
2000; Hassel et al., 2003; Rajan et al., 2003; Lee-Hoeflich et al., 2004). 
2.2 Bone morphogenetic proteins in development 
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TABLE I. Mammalian BMP family members and their type I receptors 
Ligand   Type I receptor 
Bmp2/4 group  ALK3, ALK6 BMP-2 BMP-4 
OP-1 group   ALK2, ALK6 BMP-5 BMP-6/Vgr1 BMP-7/OP-1 BMP-8a/OP-2 BMP-8b/OP-3 
GDF-5 group   ALK6 BMP-14/GDF-5/CDMP-1 BMP-12/GDF-7 BMP-13/GDF-6/CDMP-2 
BMP9/10 group  ALK1, ALK2 BMP-9/GDF-2 BMP-10 
Other members BMP-3   NF BMP-3b/GDF-10  NF BMP-11/GDF-11  ALK4, ALK5 BMP-15/GDF-9b  ALK6 BMP-16/Nodal                                                           ALK7 Abbreviations: ALK, activin receptor-like kinase; BMP, bone morphogenetic protein; CDMP, cartilage-derived morphogenetic protein; GDF, growth-differentiation factor; NF, not found; OP, osteogenic protein; Vgr, vegetal related. 
 
In Smad-dependent signaling pathway, activated type I receptors phosphorylate certain receptor-
activated Smads (R-Smads) that form a heteromeric complex with a common-mediator Smad (co-
Smad). This Smad complex translocates into the nucleus and regulates transcription of BMP target 
genes. Smads are common signal transducers of BMP and TGF-activinfamilies. R-Smads include 
Smad1/2/3/5/8, of which Smad1/5/8 are activated by BMPs (Aoki et al., 2001). There is only one co-
Smad in mammals, Smad4. In addition, there is a third class of Smads, inhibitory Smads (I-Smads), 
including Smad6/7, that negatively regulate BMP signaling through direct interactions with the type I 
receptors or with an activated R-Smads to prevent R-Smad activation or the R-Smad/co-Smad 
complex formation, respectively (Imamura et al., 1997; Nakao et al., 1997). Smad6 is specific for BMPs, 
while Smad7 is a common inhibitor in the whole TGF-superfamily. 
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Figure 6. BMP signaling pathways. Ligand binding to a heteromeric complex of BMP type I and type II receptors (BMPRI/BMPRII) phosphorylates Smad1/5/8, which complex with Smad4 and translocate into the nucleus to regulate BMP responsive genes. Alternatively, BMP receptor activation may lead to the activation of MAP kinases ERK, p38 and JNK or LIMK1 and mTOR/FRAP kinases that regulate other target genes. BMP, bone morphogenetic protein; BMPR, BMP receptor; ERK, extracellular signal regulated kinase; JNK, c-Jun N-terminal kinase; LIMK, LIM kinase; mTOR/FRAP, mammalian target of rapamycin/FKBP12-rapamycin-associated protein; P, phosphate. 
R-Smads are phosphorylated by type I receptors on their characteristic Ser-Ser-Val/Met-Ser (SSXS 
motif) in the C-terminal Mad homology 2 domain (Wang et al., 2009). As inactive proteins, R-Smads 
are localized in the cytoplasm by a nuclear export sequence (NES) (Pierreux et al., 2000; Inman et al., 
2002). Once activated, NES in the formed R-Smad/co-Smad complex is interrupted and a nuclear 
localization sequence in R-Smads guides the complex into the nucleus (Pierreux et al., 2000; Xiao et al., 
2000). 
Smad complex in the nucleus acts as a transcription factor to regulate transcription of BMP responsive 
genes by binding directly to the DNA or through interaction with other DNA-binding factors. Smads 
bind to the specific DNA sequences, a GC-rich GCCGnCGC sequence or Smad-binding element that 
is either AGAC or GTCT sequence (Kim et al., 1997; Kusanagi et al., 2000). Smads interact with 
various transcription factors, such as Runx2 and Menin in addition to other nuclear proteins (Zhang et 
al., 2000a; Sowa et al., 2004). They also bind transcriptional co-activators, including CBP/p300 that has 
histone acetyl transferase activity, as well as GCN5 and P/CAF N-acetyl transferases that enhance 
transcriptional activation (Janknecht et al., 1998; Itoh et al., 2000c; Kahata et al., 2004). 
BMP signaling is regulated by several extracellular BMP antagonists that bind BMPs and prevent 
receptor activation and subsequent signal transduction. BMP antagonists include Noggin, Chordin, 
Follistatin, Follistatin-related gene, twisted gastrulation, Ventroptin and the Dan/cerberus family genes. 
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2.2.2 BMPs during brain development 
Expression of different BMP family members is first detected in the anterior neuroectoderm before 
neural tube closure at E8.5 during the mouse development (Furuta et al., 1997). Their expression 
continues throughout the brain development and shows overlapping expression patterns in the 
dorsomedial telencephalon (Furuta et al., 1997). BMP2, BMP4 and BMP6 expression is localized in the 
dorsal neural tube, while BMP7 together with BMP4 localizes to the epidermal ectoderm (Tanabe and 
Jessell, 1996). Studies with other organisms have shown that BMP4 and BMP7 are expressed already in 
earlier stages of development in the ectoderm and their action must be inhibited in order to convert 
ectoderm into neuroectoderm (Hawley et al., 1995). In mice, BMP4 induces epidermal fate and 
concurrently inhibits neural fate (Wilson and Hemmati-Brivanlou, 1995). BMPs inhibit neurulation and 
later, they are involved in the dorsoventral patterning of the neural tube. Specifically, BMP2 inhibits the 
bending of neural folds essential for neural tube closure (Ybot-Gonzalez et al., 2007). BMP7 is 
prominently expressed in the developing mouse hindbrain and affects dorsoventral patterning of this 
area (Arkell and Beddington, 1997).  
Ectodermal BMPs induce further BMP expression in the dorsal neural tube leading to transcriptional 
activation and establishment of specific dorsal cell types, such as neural crest stem cells and dorsal 
interneurons (Liem et al., 1995; Selleck et al., 1998; Lee et al., 2000a). BMP expression at the dorsal 
neural tube forms a gradient towards the ventral side and thus, BMPs also affect the generation of 
other cell populations with co-operative and antagonistic interactions with Shh that is expressed in the 
ventral neural tube (Patten et al., 2002). BMPs also regulate rhombencephalic neural crest development 
by inducing apoptosis in specific rhombomere segments in the developing neural tube (Graham et al., 
1994). 
2.2.3 Versatile roles of BMPs in neural stem/progenitor cells 
BMP2 and BMP4 are expressed in neural stem cell-derived astrocytes, while no expression have been 
detected in NSCs themselves or in NSC-derived neurons or oligodendrocytes (Lü et al., 2009; Hu et al., 
2012). During the brain development, BMPs exert different effects on cell fate in a temporal manner: 
an early response with apoptosis following neuronal differentiation and finally glial differentiation in 
late embryogenesis (Mehler et al., 2000). BMP2 and BMP4 induce apoptosis with simultaneous 
inhibition of proliferation in cortical neural progenitor cells (Mabie et al., 1999). Furthermore, BMPs 
promote neuronal differentiation in cortical progenitors (Li et al., 1998; Mabie et al., 1999) and BMP7 
regulates the formation of dendrites in different embryonic and perinatal neuronal populations (Lein et 
al., 1995; Le Roux et al., 1999; Withers et al., 2000). BMPs promote astroglial lineage elaboration from 
embryonic neural progenitor cells with simultaneous inhibition of oligodendrocyte differentiation 
(Mehler et al., 1995; Gross et al., 1996; Mabie et al., 1999; Bonaguidi et al., 2005).  
In adult SVZ stem cell niche, BMPs inhibit neurogenesis, while promoting glial differentiation (Lim et 
al., 2000). Recently, BMP signaling was shown to induce quiescence in adult hippocampal NSCs to 
preserve the stem cell pool (Mira et al., 2010). In both adult NSC niches, Noggin antagonizes BMP 
function by recruiting the quiescent NSCs into the cell cycle and by increasing neuronal differentiation 
(Lim et al., 2000; Mira et al., 2010). 
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Proteolysis, or protein degradation, is facilitated by enzymes called proteases. Proteolysis is involved in 
different cellular events, including protein activation, removal of signal sequences or extra residues of 
proteins, and degradation of unneeded or damaged proteins or the extracellular matrix proteins. Thus, 
proteases regulate several physiological processes, including development, tissue morphogenesis and 
repair, digestion, blood coagulation, fibrinolysis, fertilization, immunity and ion and water transport. I 
will here concentrate on trypsin-like serine proteases hepatocyte growth factor activator (HGFA) and 
matriptase, and their common inhibitors that are involved in regulation of cellular behaviour. In the last 
chapter I will also unravel the mechanisms of proteasomal degradation. 
2.3.1 Serine proteases  
Serine proteases are a family of proteases among five catalytic protease classes: serine, cysteine, aspartic, 
threonine and metalloproteases (Puente et al., 2003). Serine proteases play versatile roles in both 
normal physiology and in pathological conditions, such as cancer and degenerative diseases. They 
consist of nearly or above 200 members in human and mouse, respectively (Puente et al., 2003). Serine 
residue located in the active site of protease acts as a catalytic domain. Classification of serine proteases 
is versatile but they include several subgroups and families based on their function and appearance, like 
membrane-associated or blood serum proteases. The secretion and activation of serine proteases is 
strictly regulated to limit the excess proteolytic activity. Thus after activation, their action is controlled 
by cognate endogenous inhibitors, called serine protease inhibitors (SPIs). 
HGFA is a secreted serine protease that was originally purified from bovine serum and identified as an 
activator for hepatocyte growth factor (HGF) (Shimomura et al., 1992). It is structurally similar to a 
blood coagulation factor XII (FXII) and belongs to the plasminogen activator (PA)/FXII/HGFA 
subfamily of the kringle serine protease superfamily (Miyazawa et al., 1993; 1998). HGFA is secreted as 
a zymogen, pro-HGFA, by the liver hepatocytes and it circulates in the plasma as an inactive form 
(Shimomura et al., 1993). It has detected, nonetheless, also in gastrointestinal tract, developing kidneys, 
brain astrocytes, injured and diseased brain, hair follicles and synovial tissues (Yamada et al., 1998; 
Hayashi et al., 1998; Itoh et al., 2000a; van Adelsberg et al., 2001; Lee et al., 2001; Nagashima et al., 
2001). HGFA is activated in response to tissue injury by thrombin and plasma kallikrein (Shimomura et 
al., 1993; Miyazawa et al., 1996). In tumor tissue, it is activated by kallikrein 1-related peptidases 
(KLKs) 4 and 5 (Mukai et al., 2008). HGFA activity is regulated also by endogenous inhibitors, 
including hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 as well as protein C inhibitor 
(Kawaguchi et al., 1997; Shimomura et al., 1997; Suzuki, 2010). By converting pro-HGF into an active 
αβ heterodimer, HGFA regulates tyrosine kinase receptor c-Met signaling that affects the motility, 
mitosis and morphogenesis as well as regeneration of various target cells and tissues (Naldini et al., 
1991). More recently, HGFA was found to activate macrophage-stimulating protein (MSP) important 
in regulation of macrophage activity during inflammation (Kawaguchi et al., 2009). 
HGFA-deficient mice are viable and develop normally but show impairment in regeneration of the 
intestinal mucosa after injury (Itoh et al., 2004). Although developmental abnormalities were not 
observed in HGFA knockout mice, HGFA is, however, required for kidney ontogenesis (van 
2.3 Proteolysis 
2.3.1.1 Hepatocyte growth factor activator   
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Adelsberg et al., 2001). In injured liver, HGFA facilitates tissue repair and regeneration through HGF 
activation and high-affinity binding to heparin (Miyazawa et al., 1996; Kaibori et al., 2002).  
HGFA plays a role also in tumorigenesis. Increased expression level of HGFA has been detected in 
breast cancer, colorectal carcinoma and in renal cell carcinoma compared to normal tissue (Kataoka et 
al., 2000a; Parr et al., 2004; Yamauchi et al., 2004). Furthermore, HGFA induces tumor cell invasion 
and tumor growth in glioblastoma cells (Uchinokura et al., 2006). 
Matriptase (MT-SP1, epithin) is a type II transmembrane serine protease (TTSP) characterized by a 
short signal anchor near the amino terminus, a large extracellular carboxy terminus with the serine 
protease domain and in between a stem region containing a single SEA domain, two CUB domains and 
four low density lipoprotein receptor class A domains (Figure 7). 
   
 
Figure 7. The structure of matriptase. C, carboxyterminus; CUB, complement C1r/C1s/Uegf/Bmp1 domain; LA, low density lipoprotein receptor type A domain; N, aminoterminus; PM, plasma mebrane; SEA, sea urchin sperm protein/enterokinase/agrin domain; Ser Pr, serine protease domain. Also the two cleavage sites and the four N-glycosylation sites are shown. Modified from List et al., 2006a. 
 
Among TTSPs, matriptase shares structural similarity and forms a Matriptase subfamily with 
matriptase-2 and matriptase-3 (Kim et al., 1999; Lin et al., 1999b; Velasco et al., 2002; Szabo et al., 
2005). A signal anchor orients matriptase in the plasma membrane as a membrane-associated serine 
protease. Matriptase is synthesized as catalytically inactive single-chain form, a zymogen. The life cycle 
of matriptase is unique among the serine proteases, involving an inhibitor-assisted autoactivation, rapid 
inhibition and finally shedding from the plasma membrane (Figure 8). Activation of matriptase is a 
complicated process that involves two sequential cleavages at the SEA domain and at the activation 
cleavage site in the serine protease domain (Figure 7) (Cho et al., 2001; Oberst et al., 2003b). Only the 
N terminally cleaved form of matriptase is present at the cell surface (Cho et al., 2001). The cleavage at 
the serine protease domain converts matriptase into its active two-chain form and occurs through a 
proteolytic transactivation mechanism between two matriptase zymogen molecules (Oberst et al., 
2003b). Activation involves also glycosylation of two N-glycosylation sites, Asn302 and Asn485, and is 
dependent on the interaction with a cognate inhibitor of matriptase, HAI-1 (Oberst et al., 2003b; 
2005). Autoactivation of matriptase can be triggered by a bioactive phospholipids, like sphingosine-1-
phosphate (Benaud et al., 2002). The androgen, dihydrotestosterone induces activation of matriptase in 
LNCaP prostatic adenocarcinoma cells (Kiyomiya et al., 2006). Moreover, a chemical inducer, the 
polyanionic compound suramin has been shown to stimulate matriptase activation (Lee et al., 2005a). 
2.3.1.2  Matriptase 
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Extracellular and cytoplasmic acidosis induces matriptase activation in different epithelial and 
carcinoma cells (Tseng et al., 2010). In addition, matriptase is activated by tissue acidity in different skin 
disorders (Chen et al., 2011). Shortly after its activation on the cell surface, matriptase is inhibited by 
high-affinity binding of HAI-1 resulting in the formation of a functionally inactive matriptase-HAI-1 
complex (Oberst et al., 2005). In its complexed form, matriptase is shed from the plasma membrane 
(Lin et al., 1999a). Matriptase is also inhibited by HAI-2 and sunflower trypsin inhibitor (Long et al., 
2001; Szabo et al., 2008). 
                  
Figure 8. The life cycle of matriptase. (A) Matriptase is synthesized on the rough endoplasmic reticulum (ER) as a 94 kDa full-length zymogen that is processed into a 70 kDa latent form within the ER or Golgi apparatus. (B) On the cell surface, latent matriptase undergoes auto-activation to yield a two-chain active protease that is rapidly inhibited by HAI-1 to form a 120 kDa matriptase-HAI-1 complex. This complex is targeted for proteolytic cleavage and is shed from the plasma membrane as 95 kDa and 110 kDa complexes. LDLRA, LDL receptor A; MTP, matriptase; TM, trans-membrane. Modified from List et al., 2006a and Wang et al., 2009. 
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Matriptase, as other membrane-associated proteases, facilitates its effects through proteolysis, by which 
it modulates the extracellular matrix and activates target proteins, including latent growth factors, 
cytokines, hormones and other proteases. The substrate proteins for matriptase found so far include 
protease activated receptor-2 (PAR-2), HGF, urokinase-type plasminogen activator, prostasin, MSP-1, 
PDGF-D and Trask (transmembrane and associated with src kinases) (Lee et al., 2000b; Takeuchi et 
al., 2000; Bhatt et al., 2005; Netzel-Arnett et al., 2006; Bhatt et al., 2007; Ustach et al., 2010). 
Matriptase is mainly an epithelial protease and its expression is colocalized with both HAI-1 and HAI-2 
in most epithelial tissues (Oberst et al., 2001; 2003a; Szabo et al., 2008). Matriptase is located on the 
basolateral plasma membrane and it is involved in the tight junction formation and the maintenance of 
epithelial integrity (Tsuzuki et al., 2005; List et al., 2009; Buzza et al., 2010). The physiologic function 
of matriptase is shown in matriptase null mice that die within 48 hours of birth due to an interrupted 
epidermal permeability barrier function and subsequent dehydration and hypothermia (List et al., 
2002). The same mice also reveal deficiencies in the development of hair follicles and the thymus (List 
et al., 2002). Recent studies link matriptase to the regulation of brain development. It mediates the 
activation of PAR-2 in the nonneural surface ectoderm of the developing neural tube, an event that is 
essential in neural tube closure (Camerer et al., 2010). Moreover, matriptase induces neural progenitor 
cell migration and differentiation in vitro (Fang et al., 2011). Matriptase is also present in variety of 
tumors of epithelial origin, including breast, colon, ovarian, cervical, prostate, renal, lung, skin as well as 
head and neck carcinoma where high expression levels often correlate with the malignant pathology 
(Oberst et al., 2001; 2002; Tanimoto et al., 2001; Santin et al., 2003; Jin et al., 2005; Lee et al., 2005b; 
Riddick et al., 2005; Zeng et al., 2005; Cheng et al., 2006; Jin et al., 2006; List et al., 2006b; Baba et al., 
2012). In various tumors, matriptase has a role in tumor progression mediating malignant 
transformation and tumor cell invasion (Suzuki et al., 2004; Förbs et al., 2005; List et al., 2005; Tsui et 
al., 2008). 
2.3.2 Serine protease inhibitors 
SPIs can be divided into canonical and non-canonical inhibitors and into serpins based on their 
mechanism of inhibition (reviewed in Krowarsch et al., 2003). Canonical and serpin inhibitors interact 
with a cognate protease through a binding loop complementary to the active site of the target, while 
non-canonical inhibitors bind their target through an N-terminal segment. Serpins, however, also 
induce a conformational change in the protein structure. SPIs are either single domain proteins or have 
a tandem repeat of inhibitory domains that varies between 18 serine protease inhibitor families. These 
inhibitory domains include soybean trypsin inhibitor-type, sunflower trypsin inhibitor-type, bovine 
pancreatic trypsin inhibitor/Kunitz-type and Kazal-type domains among others. 
HAI-1 and HAI-2/placental bikunin are membrane-bound glycoproteins belonging to the Kunitz-type 
serine protease inhibitor family. HAI-1 was initially identified as a potent inhibitor for secreted protease 
HGFA (Shimomura et al., 1997). Later, HAI-2 was recognized as another endogenous HGFA inhibitor 
after its homology to HAI-1 (Kawaguchi et al., 1997). The mature HAI-1 and HAI-2 proteins consist 
of two extracellular Kunitz inhibitor domains, KD1 and KD2 with varying inhibitory activity, a type-I 
transmembrane domain and a short cytoplasmic tail (Figure 9). In addition, HAI-1 contains a low 
density lipoprotein receptor (LDLR)-like domain between the KDs (Shimomura et al., 1997). HAI-1 
has a splice variant, HAI-1B that contains extra residues in adjacent to KD1, and which shares 
2.3.2.1  HAI-1 and HAI-2 
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substrate specificity and tissue expression with HAI-1 (Kirchhofer et al., 2003). HAI-2 can also be 
modified by splicing to yield a shorter form of protein that lacks the first KD. This form is the primary 
isoform in mice, while human tissues mostly express the full-length form (Itoh et al., 1999). Despite 
lacking the KD1, mouse isoform is able to inhibit HGFA (Kataoka et al., 2002). In addition, there is a 
third isoform of HAI-2 found in mouse testis that lacks the KD1 and has an insert containing a 
termination codon between the KDs in mouse cDNA, and thus it lacks also the KD2 in the final 
protein product (Itoh et al., 1999). 
                         
Figure 9. Different HAI-1 and HAI-2 isoforms. C, carboxyterminus; KD, Kunitz domain; LDLR, low density lipoprotein receptor-like domain; N, aminoterminus; TM, transmembrane domain. 
HAI-1 and HAI-2 inhibit several trypsin-like proteases that can be either secreted or transmembrane 
proteins. The inhibitory activity of both HAI-1 and HAI-2 is mostly mediated through KD1 (Qin et al., 
1998; Denda et al., 2002). They both show inhibitory activity against HGFA, hepsin, trypsin, 
matriptase, plasmin and plasma kallikrein, and HAI-2 also inhibits tissue kallikrein and several 
coagulation factors (Delaria et al., 1997; Kawaguchi et al., 1997; Marlor et al., 1997; Kataoka et al., 
2000c; Oberst et al., 2001; Denda et al., 2002; Kirchhofer et al., 2003; 2005; Szabo et al., 2008). In 
addition, HAI-1 has been recognized as an inhibitor for prostasin (Fan et al., 2005). 
Both HAI-1 and HAI-2 co-localize with matriptase in epithelial cells of most adult tissues (Szabo et al., 
2008). HAI-1 is expressed in the basolateral plasma membrane of polarized epithelial cells (Kataoka et 
al., 1999). However, the membrane-associated form of HAI-1 has a short half-life, and it is either 
secreted to the extracellular medium or recycled to endosomes or apical plasma membrane (Godiksen 
et al., 2008). In contrary, there is evidence that HAI-2 is expressed beneath the apical surface of some 
epithelial cells (Kataoka et al., 2000b). Recently, it was shown that HAI-1 is regulated by a proteolytic 
cleavage by membrane-type matrix metalloprotease MT1-MMP that induces HAI-1 shedding as 
separate fragments (Domoto et al., 2011). 
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HAI-1 and HAI-2 are essential for the proper embryonic development, and especially for the 
formation of the placenta. Homozygous deletion of HAI-1 gene in mice leads to death in utero at early 
developmental stage due to the disrupted basement membrane and lacking branching morphology of 
the labyrinth layer in the placenta (Tanaka et al., 2005; Fan et al., 2007). HAI-2 deficiency in mice also 
causes severe developmental defects, including impaired development of the neural tube and abnormal 
placental labyrinth (Szabo et al. 2009). 
Increased expression of HAI-1 is often linked to tissue injury and epithelial regeneration (Kataoka et 
al., 1999; Itoh et al., 2000b) while downregulation of both HAI-1 and HAI-2 occurs in several cancers. 
Decreased expression of HAI proteins and subsequent excessive activity of HGFA or matriptase is 
observed in breast, prostate, colorectal, renal, cerebellar and hepatocellular tumors often leading to 
malignant progression due to dysregulated protease activity (Kataoka et al., 2000b; Oberst et al., 2002; 
Kang et al., 2003; Yamauchi et al., 2004; Parr et al., 2004; 2010; Vogel et al., 2006; Tsai et al., 2007; 
Kongkham et al., 2008; Tung et al., 2009). Reduced expression of HAI proteins enhances tumor 
invasiveness, which is shown in breast, prostate, lung and pancreatic cancer cells (Cheng et al., 2009; 
Parr et al., 2010). The role of HAI-1 in tumor cell invasion is linked to regulation of epithelial-
mesenchymal transition of certain cancer cells (Cheng et al., 2009). On the other hand, forced 
expression of either HAI-1 or HAI-2 inhibits tumor cell invasion (Kongkham et al., 2008; List et al., 
2005; Tsui et al., 2008; Tung et al., 2009). 
2.3.3 Proteasomal degradation 
Two major proteolytic pathways mediate protein degradation in the cell: the lysosomal pathway and the 
ubiquitin-proteasome system (UPS). The lysosomal pathway is mainly involved in the degradation of 
membrane-associated proteins, while the UPS facilitates cytosolic protein degradation. Autophagy, 
initially considered as a non-selective degradative process, is part of the lysosomal system, where 
cytosolic components are enclosed into an autophagosome that subsequently fuses with the lysosome. 
Recently, also a selective and ubiquitin-dependent form of autophagy was discovered, where proteins 
are targeted for degradation (Shaid et al., 2012). 
The UPS is involved in protein quality control that regulates the proper folding of proteins and 
prevents the accumulation of misfolded proteins in the cytoplasm. The UPS can recognize abnormal 
proteins through molecular chaperones, heat shock proteins (Meacham et al., 2001; Murata et al., 2001; 
Marques et al., 2006). The UPS has an important role in cell division to target cell cycle regulators, like 
cyclins and CKIs, for degradation (Benanti, 2012). This enables the correct cell cycle timing and 
transitions. During neurogenesis, degradation via the UPS regulates Notch signaling and Pax6 
expression and thus, controls NSC maintenance and commitment (Tuoc and Stoykova, 2010). 
The degradation of proteins by the UPS occurs through a covalent attachment of an ubiquitin (Ub) 
molecule to the substrate protein and the following proteasomal degradation of the substrate by the 
26S proteasome (Figure 10). This involves series of enzymatic reactions, where enzymes bind Ub by a 
thiol ester (Hershko et al., 1983). First, the ubiquitin-activating enzyme, E1, binds and activates Ub in 
an ATP-dependent manner. Then, in the conjugating reaction, the Ub is transferred by an ubiquitin-
conjugating enzyme, E2, from E1 to the ubiquitin ligase (E3). The E3 recognizes the substrate protein 
and catalyzes the formation of a covalent bond between the Ub and Lys residues of the substrate. 
Usually, the substrate is polyubiquitinated for the recognition of the 26S proteasome by addition of 
2.3.3.1 Ubiquitin-proteasome system  
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several Ub monomers to form a polyubiquitin chain (Hershko et al., 1980; Pickart, 1997).  Several Lys 
residues in the Ub moiety itself serve as substrates for the subsequent ubiquitins and thus, mediate the 
formation of ubiquitin chains of variable structures (Pickart and Fushman, 2004). 
 
Figure 10. The ubiquitin-proteasome system. In the activation reaction, E1 enzyme binds ubiquitin in an ATP-dependent manner. In the following conjugation reaction, E2 enzyme carries ubiquitin from E1 to E3 enzyme that links ubiquitin to the substrate. Ubiquitin ligation is repeated to yield a polyubiquitinated substrate that is recognized by the proteasome and degraded into peptide fragments with simultaneous ATP hydrolysis. Free ubiquitin is released from the proteasome after protein degradation. Pi, inorganic phosphate; PPi, inorganic diphosphate; Ub, ubiquitin. 
 
The 26S proteasome is composed of the catalytic core, the 20S proteasome, and of the regulatory 19S 
complex (Eytan et al., 1989; Chu-Ping et al., 1994). The 20S proteasome consists of four piled 
hexameric rings made of structural α subunits and catalytic β subunits that together form a cylindrical 
structure. The two outer rings of the cylinder are formed from seven α subunits each, while the inner 
rings are each made of seven β subunits. The ring-shaped 19S regulatory particle bound to either or 
both ends of the 20S proteasome regulates substrate entry to the cylinder and serves as a gatekeeper 
(Smith et al., 2007). The degradation of proteins at the 26S proteasome is dependent on ATP hydrolysis 
and occurs through series of proteolytic cleavages of the substrate into peptide fragments, which is 
catalysed by the protease active sites in β subunits. At the proteasome, deubiquitinating enzymes release 
ubiquitin molecules from the substrate to provide free ubiquitin for the cell. 
BRUCE (BIR repeat containing ubiquitin-conjugating enzyme), also called BIRC6, belongs to 
baculoviral IAP repeat (BIR) domain-containing protein (BIRP) family. BIR domain is a hallmark of 
inhibitor of apoptosis proteins (IAPs) that form one branch of BIRP protein family. IAPs are best 
known to regulate apoptosis since they bind and inhibit the activity of caspase cysteine proteases. 
BRUCE, and other Survivin-like BIRP proteins, differs from these canonical IAPs by having extra 
amino acid residues at two concerved positions in the BIR domain (Verhagen et al., 2001). BRUCE, 
however, also exhibits an anti-apoptotic activity (Hao et al., 2004; Ren et al., 2005). In addition, the N-
terminal BIR domain of BRUCE mediates substrate binding and together with the C-terminal ubiquitin 
conjugating domain it possesses chimeric ubiquitin ligase (E3) and ubiquitin-conjugating (E2) enzyme 
activities (Hauser et al., 1998; Bartke et al., 2004). Thus, BRUCE has a unique merged function of two 
enzyme activities in ubiquitin conjugation system. 
BRUCE is a large 528 kDa membrane-associated protein that localizes to cytosolic membrane 
structures the trans-Golgi network and the vesicular system (Hauser et al., 1998). It is expressed in 
several adult tissues, being notably abundant in the brain and especially in neurons (Hauser et al., 1998; 
Sokka et al., 2005). It inhibits apoptosis through ubiquitination of different protein substrates, including 
2.3.3.2 Ubiquitin-conjugating enzyme BRUCE  
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caspases or proapoptotic proteins, like Smac/DIABLO, to facilitate their proteasomal degradation 
(Bartke et al., 2004; Qiu et al., 2005; Hao et al., 2004). In neurons, it has a protective role against 
excitotoxic nerve cell injury (Sokka et al., 2005). Moreover, BRUCE is reported to act upstream of 
tumor suppressor p53 to inhibit mitochondrial apoptosis (Ren et al., 2005). BRUCE itself is regulated 
through ubiquitination and proteasomal degradation by ubiquitin ligase Nrdp1 or by cleavage by 
caspases or serine protease HtrA2 (Qiu et al., 2004; 2005). In vivo studies suggest a physiological role for 
BRUCE to function in cell division rather than in apoptosis. BRUCE mutant mice were reported to die 
perinatally or in utero due to defects in placental trophoblast proliferation and deformation of 
conventional spongiotrophoblast layer during the development (Lotz et al., 2004; Hitz et al., 2005). 
Some in vivo studies, however, showed apoptotic cell death due to BRUCE gene-trap insertion mutation 
(Hao et al., 2004; Ren et al., 2005). The role of BRUCE in cell division is related to regulation of 
cytokinesis, during which BRUCE associates with the midbody ring to guide proper vesicle targeting 
and abscission (Pohl et al., 2008). 
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The central nervous system (CNS) and the immune system affect each other through signaling via 
hormonal cascades and neural pathways. The CNS regulates the immune system through a 
neuroendocrine system as well as locally at the site of inflammation and in immune organs (Figure 11). 
The immune system and the neuroendocrine system are important for protection against the infection 
and disease as well as for regulation of normal metabolism. The CNS signals the immune system by 
way of the hormonal stress response with the production of glucocorticoid (GC) hormones. 
Furthermore, the autonomic sympathetic nervous system secretes neurotransmitters that activate 
immune cells through specific receptors. In addition, peripheral nerves release neuropeptides that affect 
the immune system. On the other hand, the immune system regulates the CNS through production of 
cytokines by brain immune cells, which can pass the blood-brain barrier in small amounts (Banks et al., 
1995). 
 
Figure 11. The signaling of the CNS to the immune system. The CNS induces hormonal stress response and glucocorticoid (GC) secretion in response to a stressful stimulus. The autonomic nervous system interacts with the immune system by producing noradrenaline that binds to appropriate receptors in immune cells. Peripheral nerves activate the immune system by secreting neuropeptides. Modified from Bear et al., 2007, p. 207. 
2.4.1 Glucocorticoid hormones 
A classical neuroendocrine response to a stressful stimulus is the production of GC hormones, 
including cortisol and corticosterone. The secretion of GCs is regulated by a hormonal cascade called 
hypothalamic-pituitary-adrenal (HPA) axis that begins in the brain and results in the release of these 
hormones in adrenal gland (Figure 12). GCs also regulate their own levels by a feedback mechanism 
that inhibits the HPA axis. GCs are known to affect several metabolic cascades, and most organs and 
physiologic systems are sensitive to their action during the stress response. The action of GCs includes 
the release of stored energy and inhibition of glucose uptake, enhancement of gluconeogenesis and 
cardiovascular activity, suppression of the immune system and inhibition of reproductive activity. 
Prolonged excess GC secretion is a hallmark of chronic stress with increased risk of cardiovascular and 
metabolic diseases, and neuropsychiatric disorders such as depression (Tamashiro et al., 2011; Lee et al., 
2012; Datson et al., 2013). 
2.4 Interplay between the central nervous system and immune system 
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Figure 12. The hypothalamic-pituitary-adrenal (HPA) axis. A stress signal is detected in the brain cortex, which informs the hypothalamus. The hypothalamus secretes corticotropin-releasing hormone (CRH) that stimulates production of adrenocorticotropin hormone (ACTH) in the pituitary gland. ACTH reaches the adrenal gland via bloodstream and induces the expression and secretion of glucocorticoid (GC) hormones. GC secretion is regulated by GCs themselves through a negative feedback loop that inhibits the HPA pathway at the hypothalamus and pituitary level. GCs affect majority of organs and physiologic systems. Modified from Romero, 
2004. 
GCs mediate their effects via cytosolic glucocorticoid and mineralocorticoid receptors (GRs and MRs, 
respectively). Low levels of GCs bind primarily to MR, while only high levels of GCs bind to GR after 
MRs are saturated. GRs and MRs act as ligand-dependent transcription factors that regulate target 
genes either directly or via interaction with other transcription factors. 
Endogenous GCs regulate the immune system and inflammation. The physiological levels of GCs 
inhibit the immune system and have anti-inflammatory actions, while higher pharmacological levels of 
GCs totally suppress the immune activity. Moreover, most synthetic GCs show higher affinity for GR 
than natural GCs and thus, have more radical effect on the immune response. Based on these 
immunosuppressive effects, GCs such as dexamethasone are used to treat autoimmune and 
inflammatory diseases. 
GCs control various aspects of the immune system. They decrease the expression of proinflammatory 
cytokines like IL-6, TNFα and IL-1β, and upregulate the expression of anti-inflammatory cytokines. 
GCs also affect mobility of immune cells by inhibiting cell adhesion molecules involved in leukocyte 
trafficking (Cronstein et al., 1992). Through inflammatory mediators, GCs modulate immune cell 
maturation and differentiation favoring the development of T helper cell type 2 (Th2)-type adaptive 
immunity (Franchimont et al., 1998; Agarwal and Marshall, 2001). Furthermore, GCs control 
lymphocyte selection by triggering cell cycle arrest and apoptosis in lymphoid cells (Forsthoefel and 
Thompson, 1987; Ma et al., 1992; Reisman and Thompson, 1995; Rhee et al., 1995a; 1995b). Moreover, 
GCs induce apoptosis in leukemic cells and play an important role in thymocyte selection and 
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differentiation (Wyllie, 1980; Iwata et al., 1991; Thulasi et al., 1993; Ramdas and Harmon, 1998; 
Vacchio et al., 1998; Schmidt et al., 2001). 
In the adult brain, GCs secreted during the stress response suppress glucose transport in neurons and 
glial cells and reduce synaptic plasticity in hippocampus (Horner et al., 1990; Virgin et al., 1991; 
Pavlides et al., 1993). Thus, GC secretion may disrupt memory formation and contribute to 
neurotoxicity. In addition, GCs have negative impacts on adult hippocampal neurogenesis (Cameron 
and Gould, 1994). On the other hand, GCs have been reported to activate Trk neurotrophin receptors, 
and to facilitate neuroprotection in neurons deprived of trophic support (Jeanneteau et al., 2008). 
Dexamethasone is a commonly used synthetic glucocorticoid hormone. It exhibits anti-inflammatory 
role by downregulating IL-1β and inhibiting binding of transcription factor complexes on TNF-α 
promoter and thus, distorting TNF-α synthesis (Lee et al., 1988; Steer et al., 2000). Dexamethasone has 
been suggested to induce the shift from the Th1 type innate immunity to the Th2 phenotype by 
differentially regulating IL-10 and IL-12 expression after endotoxin stimulation (Visser et al., 1998) and 
because of its more efficient downregulation of Th1-type cytokines than Th2-type cytokines 
(Franchimont et al., 1998). Dexamethasone affects immune cell trafficking by suppressing 
lipopolysaccharide (LPS)-induced adhesiveness of leukocytes to endothelial cells in a GR-dependent 
manner (Cronstein et al., 1992). In addition, it increases leukocyte mobility through downregulation of 
an adhesion molecule L-selectin (Nakagawa et al., 1999). Dexamethasone also reduces the expression 
of chemoattractants required for immune cell accumulation at sites of inflammation, including IL-5, 
RANTES, eotaxin and CINC/gro, (Ohtsuka et al., 1996; Wingett et al., 1996; Lilly et al., 1997; Sewell et 
al., 1998).  
Dexamethasone has a negative impact on cell division as it controls the expression of many critical cell 
cycle regulators. Dexamethasone suppresses c-myc transcription and the expression of cyclin D3 and 
cdks in lymphoid cells, and induces growth arrest at G1 phase (Forsthoefel and Thompson, 1987; Ma 
et al., 1992; Reisman and Thompson, 1995; Rhee et al., 1995a; 1995b). Dexamethasone also affects 
neural progenitor cell division by inhibiting their cell cycle through ubiquitin-mediated degradation of 
cyclin D1 (Sundberg et al., 2006). 
2.4.2 Neuropeptide PACAP 
Neuropeptides are signaling molecules that are secreted by neuronal cells and, which facilitate cell 
communication. Neuropeptide PACAP has been discovered as a regulatory peptide in hypothalamus, 
and it is shown to stimulate adenylyl cyclase activity and cyclic adenosine monophosphate (cAMP) 
formation in the pituitary (Miyata et al., 1989). PACAP is a neuropeptide that shares three receptors 
with the vasoactive intestinal polypeptide, named PAC1, VPAC1 and VPAC2 (Harmar et al., 1998). 
PACAP is expressed in the brain as well as in several peripheral organs. In the brain, it is most 
abundantly expressed in the hypothalamus but it is also found in various other brain regions (Köves et 
al., 1991; Ghatei et al., 1993; Hannibal, 2002). Among peripheral organs, PACAP is highly present in 
most endocrine organs, including pituitary gland and adrenal gland, as well as testis, lymphoid organs 
and gastrointestinal tract (Arimura et al., 1991; Gaytan et al., 1994; Abad et al., 2002; Mazzocchi et al., 
2002). PACAP and its PAC1 receptor are also present in the neurogenic region of the developing brain 
suggesting a role for PACAP in neurogenesis (Waschek et al., 1998; Jaworski and Proctor, 2000). 
2.4.1.1  Dexamethasone 
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PACAP is traditionally known for its ability to act as a neuroprotective and neurotrophic peptide. It 
protects cortical and retinal neurons against glutamate-induced neurotoxicity (Morio et al., 1996; Shoge 
et al., 1999) and promotes neuronal survival in different embryonic and postnatal neuronal populations 
indicating an important role in neuronal development (Lindholm et al., 1998; Lioudyno et al., 1998; 
Takei et al., 1998; 2000). In cerebellar granule neurons it inhibits apoptosis by regulating caspase-3 
activity (Vaudry et al., 2003). Moreover, PACAP protects neurons from ischemic death (Dohi et al., 
2002; Reglodi et al., 2002; Tamas et al., 2002; Chen et al., 2006; Stumm et al., 2007). PACAP exhibits 
neurotrophic effects in dorsal root ganglion neurons and in mesencephalic dopaminergic neurons, 
where it promotes neurite outgrowth or enhances dopamine uptake and tyrosine hydroxylase 
expression, respectively (Lioudyno et al., 1998; Takei et al., 1998). Furthermore, it is able to 
transactivate Trk tyrosine kinase receptors on the intracellular membranes such as Golgi, and increase 
neuronal cell survival in the absence of neurotrophin binding (Lee et al., 2002; Rajagopal et al., 2004). 
In addition, it has been shown to act as a non-cholinergic neurotransmitter that is secreted from 
cholinergic nerve terminals and required for sustained release of catecholamines (Wakade, 1988; 
Hamelink et at., 2002). 
PACAP serves as an anti-inflammatory peptide and displays cytoprotective effects also in cells and 
tissues outside the brain, including kidneys, intestine, pancreas, heart, lungs and skin. The anti-
inflammatory role of PACAP has been shown in several studies with PACAP-deficient mice 
(Armstrong et al., 2008; Azuma et al., 2008; Nemetz et al., 2008; Kemeny et al., 2010; Elekes et al., 
2011). PACAP also protects against autoimmune diseases, such as experimental autoimmune 
encephalomyelitis (EAE), which is an animal model of multiple sclerosis (MS) (Kato et al., 2004). 
2.4.3 Neuroinflammation 
Neuroinflammation is not considered as a classical inflammation with signs of redness and swelling but 
involves activation of microglia in the nervous system as well as involvement of perivascular 
macrophages and astrocytes (Graeber et al., 2011). Inflammation involves invasion of circulating 
immune cells to the tissue, and production of proinflammatory cytokines and chemokines. However, 
the blood-brain barrier in the brain restricts the entry to the CNS by peripheral immune cells and large 
molecules, including immunoglobulins, cytokines and complement proteins. In addition to activated 
microglia, neuroinflammation is characterized by production of neurotransmitters and reactive oxygen 
species (ROS). It occurs due to tissue trauma or injury or exposure to pathogens. Neuroinflammation is 
present both in the healthy brain, where it is required for tissue repair as a strictly regulated 
inflammatory process, and under pathological conditions. It may result in the development or 
progression of different neuronal disorders, including Alzheimer´s disease, Huntington´s disease, 
Parkinson´s disease, MS, amyotrophic lateral sclerosis (ALS), epilepsy and major depression (Raison et 
al., 2006; Qian et al., 2010). 
Microglia belong to glial cells but is distinquished from macroglia, including astrocytes and 
oligodendrocytes, by their origin, morphology and function. Microglial cells are of myeloid origin and 
arise from yolk sac macrophages that scatter into the brain during early embryogenesis and differentiate 
into microglial cells (Saijo and Glass, 2011). In a resting state, as they appear in the healthy brain, 
microglia are characterized by a ramified appearance with motile processes that continuously monitor 
the surroundings in the CNS (Nimmerjahn et al., 2005).  
2.4.3.1 Microglia 
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Microglia participate in maintenance of brain homeostasis. They support synaptogenesis and neuronal 
survival as well as the growth of regenerating axons in injured brain by secreting neurotrophic factors, 
including nerve growth factor, brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic 
factor (GDNF) and neurotrophin-3 (Elkabes et al., 1996; Honda et al., 1999; Batchelor et al., 2002; 
Bessis et al., 2007). They also play an essential role in synaptic pruning in maturing brain (Paolicelli et 
al., 2011). Moreover, during the brain development, microglia support neurogenesis by inducing 
apoptosis and phagocytosing apoptotic cells to balance the neuronal cell number (Ashwell, 1990; 
Egensperger et al., 1996; Sierra et al., 2010). 
Neuroinflammation induces activation of microglia in response to injury, ischemia or inflammatory 
stimuli, leading to their conformational change into an amoeboid–like phenotype. Reactive microglia 
migrate along a chemotactic gradient and secrete chemokines to recruit more microglial cells to the site 
of inflammation (Nolte et al., 1996; Garden and Möller, 2006). Microglia recognize various pathogen-
associated molecular patterns found on bacteria and viruses through binding by pattern-recognition 
receptors (PRRs), including Toll-like receptor 4, which recognizes LPS on the outer membrane of 
Gram-negative bacteria (Bauman et al., 2009). Activation of PRR-mediated signaling in microglial cells 
induces the production of inflammatory mediators, like cytokines, chemokines, ROS and nitric oxide 
(NO) that play a role in innate immunity. On the other hand, microglia also upregulate major 
histocombatibility complex class II molecules for antigen presentation to T cells (O’Keefe et al., 2002). 
Thus, microglia facilitate both innate and adaptive immunological responses of the nervous system. 
Moreover, microglia participate in tissue repair by phagocytosing cellular debris after recognition of  
endogenous damage-associated molecular patterns released from damaged or dying cells (Chen and 
Nunez, 2010). 
Microglia have been shown to propagate inflammatory response by activating brain astrocytes, which 
leads to the accumulation of neurotoxic factors (Saijo et al., 2009). Proinflammatory cytokines and 
neurotoxins NO and ROS secreted by reactive microglia may cause neuronal damage by enhancing 
oxidative stress and by inducing neuronal cell death. Activation of microglia is described in several 
neurodegenerative diseases, where they contribute to disease pathogenesis. Death of dopaminergic 
neurons in Parkinson’s disease activates microglia but, on the contrary, reactive microglia also induces 
dopaminergic neuronal death (Dutta et al., 2008; Cao et al., 2011). Widespread microglial activation is 
also detected in the brain of patients with ALS (Turner et al., 2004). In Alzheimer’s disease, aggregated 
amyloid-β proteins characteristic in disease pathology, activate microglial receptors (Landreth and 
Reed-Geaghan, 2009; Yan et al., 2009). Furthermore, microglia is involved in Huntington’s disease 
pathophysiology (Sapp et al., 2001) as well as in the emergence of MS (Priller et al., 2001). 
Interferon-gamma (IFN) belongs to interferon family of cytokines that were originally discovered by 
their interfering effects on viral replication (Isaacs and Lindenmann, 1987). IFN alone constitutes a 
type II IFN class. It is secreted by an array of immune cells, including lymphocytes, natural killer (NK) 
cells, B cells and antigen-presenting cells. IFN signals through IFN receptor (IFNR) composed of 
two IFNR1 chains associated with two IFNR2 chains (Figure 13). IFNR lacks intrinsic 
kinase/phosphatase activity but it associates with JAK/STAT signaling machinery for signal 
transduction. Binding of IFN to the receptor induces sequential phosphorylation in JAK2 and JAK1, 
the latter of which then phosphorylates each IFNR1 chain (Igarashi et al., 1994; Briscoe et al., 1996). 
After IFNR phosphorylation, STAT1 is able to bind to the receptor and is phosphorylated by JAK2 
2.4.3.2 Interferon-gamma 
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(Briscoe et al., 1996). STAT1 then dissociates from the receptor and enters the nucleus to regulate 
transcription of IFN-regulated genes. IFN signaling is regulated by the endosomal pathway that 
internalizes the IFN-IFNR complex after signal transduction and degrades the ligand (Anderson et 
al., 1983; Celada and Schreiber, 1987). IFN secretion is upregulated by cytokines IL-12 and IL-18 
(Munder et al., 1998; Pien et al., 2000; Schindler et al., 2001) and inhibited by IL-4 and IL-10 (Fukao et 
al., 2000; 2001; Schindler et al., 2001). 
     
 
Figure 13. IFN-induced JAK/STAT signal transduction. Ligand binding to IFNR complex induces autophosphorylation of JAK1 and JAK2 with subsequent phosphorylation of IFNR1 chain by JAK1. STAT1 is then recruited to the receptor and phosphorylated by JAK2. Phosphorylated and dimerized STAT1 translocates to the nucleus and regulates IFN-responsive genes. IFN, interferon; IFNR, IFN receptor; JAK, Janus tyrosine kinase; P, phosphate; STAT, signal transducers and activators of transcription. 
Alongside the more classical antiviral type I interferons containing IFNα and IFNβ, also IFN mediates 
antiviral defense mechanisms (Müller et al., 1994). IFN regulates a plethora of immune functions by 
enhancing antigen presentation and immune cell trafficking as well as growth, maturation and 
differentiation of immune cells. Especially, IFN primes macrophage responses and activates their 
microbicidal effector functions by regulating the class I and class II antigen presentation pathways 
(Fellous et al., 1982; Shirayoshi et al., 1988; Figueiredo et al., 1989; Johnson et al., 1990). It is known to 
activate various cell types involved in immune function, including macrophages, NK cells and 
astrocytes (Nathan et al., 1983; Fierz et al., 1985; Carnaud et al., 1999). IFN promotes Th1-type 
immunity but also the transition from innate immunity to adaptive immunity (Gajewski and Fitch, 
1988; Collins and Dunnick, 1993; Yoshida et al., 1994). IFN also regulates cell growth by inhibiting 
cell cycle progression (Mandal et al., 1998; Ramana et al., 2000). IFN may also induce proliferation or 
protect from apoptosis (Novelli et al., 1996) by upregulating a number of proapoptotic proteins, such 
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as interferon regulatory factor 1, Fas and Fas ligand (Sims et al., 1993; Xu et al., 1998). Moreover, IFN 
controls leukocyte attraction via upregulation of several chemokines and adhesion molecules. 
IFN is involved in the pathology of autoimmune diseases, such as MS (Panitch et al., 1987). However, 
it is also shown to diminish morbidity in mice with EAE (Billiau et al., 1988). 
IFN affects the brain at the level of neuroendocrine system as well as neuronal survival and 
neurogenesis. It reduces secretion of adrenocorticotropin hormone, growth hormone and prolactine 
from the pituitary in cell culture system (Vankelecom et al., 1990). IFN is best known to be toxic for 
neurons as shown in neuron-glia co-cultures (Jeohn et al., 2000; Sohn et al., 2007) but it can also 
stimulate neurogenesis, neuronal differentiation and neurite outgrowth (Wong et al., 2004; Song et al., 
2005; Baron et al., 2008). Moreover, it affects neural progenitor cells by enhancing neurosphere 
formation in the embryonic brain, while showing inhibitory effects in the adult brain (Li et al., 2010). 
Activation of NPC proliferation by IFN is mediated through induction of Shh, an essential factor in 
NPC development (Li et al., 2010; Sun et al., 2010). As being involved in the immune function, in 
neuroendocrine system and in CNS, IFN is a potent mediator of communication between these 
systems. 
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Neural stem/progenitor cells provide a platform for the development of the central nervous system 
and the cells are dependent on diverse signals that reach them from the surrounding. Cell surface-
associated proteins may facilitate cell-to-cell interactions or transform extrinsic signals into the cells. 
Interactions between brain cells and immune cells mediate the interplay of the CNS and the immune 
system, and are orchestrated by hormones and inflammatory mediators that influence NPC 
development. The aims of this study were to address the effects of membrane-associated proteins and 
brain inflammation on NPCs. 
The specific aims of this study were: 
I To characterize the role of BRUCE in the glucocorticoid hormone dexamethasone-mediated 
effects on NPC proliferation 
II To investigate the role of neuroinflammation and the cytokine IFN in NPC survival 
III To study the involvement of cell surface protease inhibitors HAI-1 and HAI-2 in the regulation of 
NPC behavior and cell fate in the developing brain
3 AIMS OF THE STUDY 
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The detailed descriptions of the materials and methods are found in the original publications. 
Wistar rats obtained from Harlan (Horst, The Netherlands) and used in studies I-III were mated at 10-
12 weeks of age. NMRI mice used in study III were obtained from own breeding. All animal 
experiments were approved by the local ethical committee and accomplished in accordance with the 
European Communities Council Directive (86/609/EEC). 
TABLE II. Cell types used in the study 
Cell type   Publication E17 hippocampal neurons  III microglia   II neural progenitor cells  I-III p53 deficient mouse embryonic fibroblasts II radial glial  cells  III 
 
NPCs and hippocampal (HC) neurons were isolated from embryonic day 17-18 (E17-E18) rat brain 
striatum and hippocampus, respectively. Pregnant rats were anaesthetized with carbon dioxide and 
killed by decapitation or cervical dislocation. The embryos were collected to sterile phosphate buffered 
saline (PBS) and placed on ice. The striatal tissue and hippocampi were dissected from the embryonic 
brains. The striatal tissue was dissociated in a Hank´s buffered saline solution (HBSS) containing 15 
mM Hepes, 2 mM glucose, 1.3 mg/ml trypsin, 0.2 mg/ml kynurenic acid, 0.7 mg/ml hyaluronidase and 
20 g/ml DNase. Dissociation enzymes were inactivated with Earle´s balanced salt solution (EBSS) 
containing 20 mM Hepes and 4% BSA, and the cells were passed through a 70 m nylon cell strainer, 
followed by centrifugation at 2000 rpm for 5 min. The cells were resuspended and placed on top of a 
30.8% sucrose gradient in HBSS and centrifugated for 7 min at 2000 rpm. After an additional 
centrifugation at 2000 rpm for 5 min through 20 mM Hepes and 4% BSA in EBSS, cells were 
resuspended in serum-free cell culture medium containing DMEM/F12 supplemented with L-
glutamine, penicillin-streptomycin, B27 and epidermal growth factor (20 ng/ml). Isolated NPCs were 
plated on nonadherent culture dishes at a density of 5x106 cells per 10 cm dish. Cells formed 
neurospheres within 2-3 days and were grown for two passages before use in experiments. 
Neurospheres were dissociated and the medium was changed in every four or five days.  
The dissected hippocampi were incubated with 1 mg/ml bovine serum albumin (BSA), 0.5 mg/ml 
papain and 0.2 mg/ml cystine in PBS for 15 min at +37°C. The cells were gently dissociated in the 
presence of 20 g/ml DNase, collected by centrifugation and plated on poly-DL-ornithine-coated 6-
well plates at a density of 2x106 cells per well in Neurobasal medium supplemented with B27, L-
glutamine and 25 M glutamate. Medium was replaced after 4-6 hours and the cells were cultivated in 
Neurobasal medium with L-glutamine and B27 supplement for 7 days. 
Microglial cells were prepared from postnatal day (P) 1-2 rat brain cortex. The tissue was minced and 
passed through a stainless steel mesh, dissociated and washed by centrifugation. Cells were resuspended 
4 MATERIALS AND METHODS 
4.1 Animals 
4.2 Cell culturing 
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in DMEM/F12 medium containing 10% fetal bovine serum (FBS) and penicillin-streptomycin, and 
cultured for up to three weeks on 75cc flasks with medium addition twice a week. 
p53 deficient mouse embryonic fibroblasts were cultured in DMEM medium with 10% FBS, L-
glutamine and penicillin-streptomycin, and passaged when 70-80% confluent. 
Radial glial cells were differentiated from mouse embryonic stem cells (ESCs). ESCs cultured on mouse 
embryonic fibroblast feeder cells in knockout-DMEM medium with 15% fetal calf serum (FCS), 
1000U/ml LIF, penicillin-streptomycin, non-essential amino acids and -mercaptoethanol, were 
deprived of feeders and used for embryoid body (EB) formation. EBs were cultivated in the presence 
of only 10% FCS and without LIF for four days following addition of 5 µM retinoic acid for additional 
four days to induce neuronal differentiation. EBs were dissociated and plated onto poly-DL-lysine and 
laminin-coated dishes in N2B27 medium, a 1:1 mixture of DMEM/F12 and Neurobasal media 
supplemented with N2 and B27 to induce radial glial phenotype. 
NPC neurospheres were dissociated into single cells and plated onto poly-DL-ornithine-coated 24-well 
culture dishes and fixed with 4% paraformaldehyde (PFA) after two hours or 5 days in order to study 
proliferation or differentiation, respectively. Washed cells were subjected for immunocytochemistry 
using proliferation markers Ki67 or BrdU (after BrdU pulse for 24 hours in cells) and differentiation 
markers III-tubulin, GFAP and CNPase. The number of immunopositive cells was determined using 
microscopy in four independent fields per coverslip. 
Self-renewal was assayed by plating equal amounts of NPCs and incubating cells for three days 
followed by estimation of the number of newly formed neurospheres. 
For cell cycle analysis, NPCs were washed with ice-cold PBS, fixed with PFA and permeabilized with 
MeOH. The cells were then pretreated with RNAse A, and stained with propidium iodide. Cells were 
analyzed with flow cytometry using a FACS calibur flow cytometer. 
NPC survival was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay or by counting the number of condensed/apoptotic nuclei stained with Hoechst 33342. 
Cell death was quantified by staining of fragmented DNA with propidium iodide or terminal 
deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL). 
Overexpression and downregulation assays for NPCs were performed using the Amaxa nucleofector 
transfection system to introduce plasmids, oligonucleotides or siRNA (Table III) into cells. 
Dissociated NPCs were transfected by electroporation according to manufacturer´s protocol and the 
cell culture medium was replaced 24 hours after transfection. In some overexpression studies, the 
transfected cells were selected with 600 g/ml of G418. 
 
 
4.3 NPC proliferation and differentiation assay 
4.4 NPC self-renewal and cell cycle analysis 
4.5 NPC viability and cell death assays 
4.6 Amaxa Nucleofector system 
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TABLE III. Plasmids, oligonucleotides and siRNAs used in the present study. 
DNA/RNA   Source   Publication p3xFlag-CMV10-BRUCE  Hao et al., 2004  I BRUCE AS oligonucleotides  Interactiva   I BRUCE siRNA   Ambion   I Cyclin D1 siRNA  Ambion   I HAI-1 siRNA   Ambion   III HAI-2 siRNA   Ambion   III p21 siRNA   Dharmagon   II p53 siRNA   Dharmagon   II pCAG-hHAI-1   Koivuniemi et al., 2013  III pCIneo-hHAI-1   Kataoka et al., 2000c  III pCIneo-hHAI-1dTM  Miyata et al., 2005  III pCIneo-hHAI-2   Kataoka et al., 2000c  III pCIneo-hHAI-2dTM  Kataoka, H.   III pGEMT-Usp8/Ubpy  Row et al., 2007  I 
 
Microglia conditioned medium was collected after 24 hour-stimulation of microglial cells with LPS and 
used for enzyme-linked immunosorbent assay (ELISA) with the rat Quantikine kit to measure the 
amount of IFN. 
4% PFA-fixed NPCs on 24-well cell culture plates were blocked with 3% BSA in PBS or 
PBS/0.1%Triton-X-100 (PBS-T) and subjected for primary antibody incubation for overnight at +4°C 
in blocking solution. On the following day, cells were washed and incubated with fluorescent Alexa or 
Cy-conjugated secondary antibodies for 1 hour at RT, after which cells were counterstained with 4 
µg/ml Hoechst 33342 and mounted. 
Paraffin sections from E17 and P1 rat brains were dewaxed in xylene and rehydrated in decreasing 
ethanol series and water. Sections were subjected for antigen retrieval by boiling the sections in 10 mM 
citrate, pH 6.0. Sections were blocked with 5% BSA/PBS(-T) and incubated with primary antibodies in 
3% BSA/PBS(-T) for overnight at +4°C. Fluorescent Alexa or Cy-conjugated secondary antibodies 
were diluted in 3% BSA/PBS(-T) and added for sections for 1 hour before counterstaining with 4 
µg/ml Hoechst 33342 and mounting. 
Frozen sections from E15 and P1 mouse brains were melted and fixed with ice-cold acetone-methanol 
(1:1). Sections were subjected to antigen retrieval as above and washed with PBS-T before blocking 
with 5% BSA/PBS-T. Primary antibodies diluted in 3% BSA/PBS-T were added for sections for 
overnight at +4°C. On the following day, fluorescent secondary Alexa antibodies were added for 
sections for 1 hour before counterstaining with 4 µg/ml Hoechst 33342. Sections were rinsed with 70% 
ethanol and mounted. 
Primary antibodies used are shown in Table IV. 
 
 
4.7 ELISA 
4.8 Immunochemistry 
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TABLE IV. Primary antibodies used in the study. 
Antibody  Host Source                Publication           Method 
β-Actin  rabbit Sigma  I-III WB Bad  rabbit Cell Signaling  II WB Bax  rabbit Santa Cruz  II WB BclXL  rabbit BD Biosciences  II WB BrdU  rat Sigma  I-III ICC, IHC BRUCE  mouse BD Biosciences  I ICC, IHC, WB Caspase 3  rabbit Cell Signaling  II WB Cleaved caspase 3 rabbit Cell Signaling  II WB c-Met  mouse Cell Signaling  III WB CNPase  mouse Sigma  III ICC 
β-COP  rabbit Abcam  I ICC Cyclin D1  mouse Santa Cruz  I-III WB Cytochrome c  mouse BD Biosciences  II ICC Erk1/2  rabbit Cell Signaling  III WB GFAP  rabbit Sigma  I, III ICC, IHC HAI-1  rabbit Santa Cruz  III IHC, WB HGF  rabbit Santa Cruz  III WB HGFA  goat Santa Cruz  III WB hHAI-2 mAb 2N9 mouse Kataoka et al., 2000c III WB mHAI-1  goat R&D Systems  III ICC mHAI-1 pAb  rabbit Tanaka et al., 2005 III WB mHAI-2  goat R&D Systems  III ICC mHAI-2 pAb  rabbit Kataoka et al., 2002 III WB IFN  rat R&D Systems  II cell inhibition IFNR2  mouse Abcam  I ICC, IHC, WB Ki67  mouse BD Biosciences  I-III ICC, IHC MG2 mAb  mouse Hallikas et al., 2006 III cell inhibition Nestin  mouse Millipore  II, III ICC, IHC Nestin  goat R&D Systems  II ICC, IHC Nrdp1  rabbit Bethyl Laboratories I IP, WB p21  mouse Millipore  II WB p53  mouse Cell Signaling  II IP, WB PARP  rabbit Cell Signaling  II WB P-Bad  rabbit Cell Signaling  II WB P-Erk1/2  rabbit Cell Signaling  III WB P-Smad1/5/8  rabbit Cell Signaling  III ICC P-Stat1  rabbit Cell Signaling  II ICC, WB PUMA  rabbit Cell Signaling  II WB P-Vimentin  mouse Assay Designs  II WB 
α-Spectrin  mouse Chemicon  I WB Stat1  rabbit Cell Signaling  II WB St14  rabbit Abcam                unpublished data ICC, WB Tau  rabbit Sigma  I ICC 
βIII-tubulin  mouse Covance  III ICC  Usp8  rabbit Abcam  I WB Abbreviations: ICC, immunocytochemistry; IHC, immunohistochemistry; IP, immunoprecipitation; WB, western blotting. 
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Whole mount in situ hybridization was performed for E17 rat brain sections embedded in agarose that 
were cut with Leica VT 1000S Vibratome. Sections were preincubated with Proteinase K, hybridized 
using digoxigenin-labelled cRNA probes and the InSituPro automate and mounted. 
Exposed E14 or E17 mouse embryos were injected with expression plasmids through the uterine wall 
into the lateral ventricle of the brain and electroporated using a square-wave pulse generator in a dorsal 
to lateral direction. After 5 pulses, the uteri were placed back in the abdominal cavity that was sutured. 
Brains were collected at E15 or P1, respectively, fixed with 4% PFA overnight and immersed with 30% 
sucrose in PBS. 
NPCs and hippocampal neurons were lysed in ice-cold RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-
40, 0.25% sodium deoxycholate, 150 mM NaCl and 1 mM EDTA) with or without 1% SDS and 
supplemented with protease inhibitor cocktail. For phosphatase inhibition in some experiments, 
phosStop solution was added to the lysis buffer. Equal amount of proteins were separated by SDS-
PAGE, transferred to a nitrocellulose membrane and blocked with 5% skimmed milk or BSA, followed 
by incubation with primary antibodies (Table IV) overnight at +4°C. Horseradish peroxidase-
conjugated secondary antibodies were added on the membrane for 1 hour, followed by washes and 
detection using the enhanced chemiluminescence. 
Immunoprecipitation of NPCs was performed using the protein A-sepharose or protein G agarose. 
Lysates in IP lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, and 0.5% sodium 
deoxycholate) were prepurified with sepharose/agarose and incubated with a primary antibody for 
overnight. A total of 40 μl of sepharose/agarose was added to lysates for two hours followed by washes 
with IP washing buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.1% NP-40, and 0.05% sodium 
deoxycholate). Sepharose/agarose beads were boiled and proteins were subjected for immunoblotting. 
Total RNA from cultured cells was extracted using the GenElute Mammalian total RNA kit. cDNA 
was prepared using the reverse transcriptase kit or the SuperScript VILO cDNA synthesis kit for 
reverse transcriptase (RT)-PCR and quantitative PCR, respectively. Strand-specific cDNA was prepared 
using the RevertAid Premium reverse transcriptase. In RT-PCR, β-actin was used as a control. 
Quantitative PCR was performed with the Power SYBR Green PCR Master mix and using the ABI 
PRISM 7000 sequence detection system, or with the LightCycler® 480 SYBR Green I Master Mix and 
using the LightCycler® 480 II system. Samples were run in triplicates and the comparative CT method 
was used for data analysis. GAPDH was used as an internal control gene. 
Primers used for PCR are shown in Table V. 
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TABLE V. Primers used for PCR analysis. 
Gene Forward primer  Reverse primer 
Bmp2 5’-TCCATCACGAAGAAGCC-3’  5’-ACTGACTTGTGTTCTGAG-3’ 
Bmp4 5’-AGCCAACACTGTGAGGAG-3’ 5’-TGTCTGGTGGAGGTGAGT-3’ 
BMPRIA 5’-AGCCTGTCTGTTCATCATT-3’ 5’-CAGAGCCTTCATACTTCAT-3’ 
BMPRIB 5’-TACCTCATCACAGACTATC-3’ 5’-CTAATGAACTTGACAGCCA-3’ 
Bruce 5’-CTCTTACTCCGAGCGAT-3’  5’-CTTAACAGGGGGAGGC-3’ 
c-Met 5’-ATAGAGTGGAAGCAAGC-3’  5’-GCACTTACAAGCCTATC-3’ 
HAI-1 5’-GAGCAGAACTTCGTGTG-3’  5’-GTAGTTGTTCTTGTTGCC-3’ 
HAI-1 qPCR 5′-GCCAGCATCTCTACGGTCT-3′ 5′-ACGGCAGCTCGGTCTCA-3′ 
HAI-2 5’-ATGAAGAATACTGTGTCC-3’ 5’-GCTGCTCCTTGTCATC-3’ 
HAI-2 qPCR 5’-GGCTGTGAGGGAAATGGTAA-3’ 5’-ACCATCAATGGTGTTCTCAGTG-3’ 
Noggin 5’-AGCACTATCTACACATCCG-3’ 5’-CACAGACTTGGATGGCTTA-3’ 
p21 5’-AGGCAGACCAGCCTAACAGA-3’ 5’-CAGCACTAAGGAGCCTACCG-3’ 
SOCS1 5’-AGCAGCTCGAAAAGGCAGTC-3’ 5’-ACACTCACTTCCGCACCTTC-3’ 
SOCS3 5’-ACCAGCGCCACTTCTTCACG-3’ 5’-GTGGAGCATCATACTGATCC-3’  
Fluorescence images were captured with the Leica DM 4500B microscope, the Zeiss Axio Observer Z1 
inverted microscope or with the Zeiss LSM 510 Meta confocal microscope. Brightfield images were 
taken with the Leica DM 4500B microscope. 
Western blots and RT-PCR results were quantified with ImageJ software. 
Cell counting after immunochemistry was performed manually using microscopy in at least four non-
overlapping fields per coverslip. 
All experiments were repeated at least three times. Statistical comparisons were performed using 
Student’s t-test or one-way ANOVA and a Bonferroni post hoc test. P value p < 0.05 was considered as 
statistically significant. 
4.13 Image analysis and statistics 
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5.1.1 Dexamethasone reduces NPC proliferation by downregulating BRUCE 
Dexamethasone is a synthetic glucocorticoid hormone used to treat immune disorders due to its 
immunosuppressive effects. Glucocorticoid production is increased after a stressful stimulus that leads 
to the use of energy stores and activation of vital functions with simultaneous inhibition of non-
necessary functions, like cell growth. Dexamethasone is known to inhibit cell division, which is also 
observed in NPCs (Sundberg et al., 2006). It reduced the amount of proliferating Ki67-positive cells in 
culture (I/Fig. 3). In addition, dexamethasone was shown to decrease the expression of BRUCE both 
at the mRNA and protein level (I/Fig. 3). BRUCE is an anti-apoptotic protein that belongs to a BIRP 
family of IAP proteins, and which bears an additional ubiquitin-conjugating enzyme activity (Hauser et 
al., 1998). In the present study, BRUCE was shown to be expressed in the developing neurogenic 
region of the brain (I/Fig. 1). In cultured NPCs it colocalized with the Golgi marker, β-COP in 
intracellular membrane structures as well as to differentiated cells exhibiting Tau-positive neuronal 
character (I/Fig. 1). BIRP proteins, like Survivin, have been shown to affect cell division (reviewed in 
Johnson and Howerth, 2004) so we addressed the role of BRUCE in both proliferation and cell 
survival of NPCs. BRUCE downregulation with specific antisense oligonucleotides decreased NPC 
viability measured by MTT assay but did not induce cell death as a cell death inducer staurosporine did 
not enhance BRUCE downregulation-mediated decrease in NPC viability (I/Fig. 2). Moreover, 
BRUCE oligonucleotide transfection did not affect the number of fragmented nuclei in NPC 
population after staining with propidium iodide (I/Fig. 2). Inhibition of BRUCE with siRNA, on the 
other hand, affected NPC proliferation and decreased the amount of Ki67-positive cells in culture 
(I/Fig. 2).  
In NPCs, BRUCE may be involved in the regulation of cytokinesis, as shown previously by Pohl et al. 
(2008) in other cell cultures. Dexamethasone-induced decrease in NPC proliferation was attenuated by 
overexpression of BRUCE (I/Fig .3), further confirming the role of BRUCE in NPC division. Infact, 
in vivo studies have indicated an important role for BRUCE in cell proliferation during early 
embryogenesis (Lotz et al., 2004; Hitz et al., 2005). BRUCE acts in the final steps of protein 
ubiquitination, which proposes that it may regulate inhibitory cell cycle proteins by ubiquitination to 
promote cell division. In line with this, BRUCE is able to inhibit tumor suppressor p53Kip2, a protein 
that also controls cell proliferation, in a process of apoptosis (Ren et al., 2005). 
Dexamethasone affected BRUCE both at the mRNA and protein level through activation of 
glucocorticoid receptors, shown by simultaneous treatment of cells with GR antagonist, mifepristone, 
that inhibited dexamethasone-mediated effects on BRUCE expression (I/Fig. 3). BRUCE mRNA 
expression was, however, recovered after 12 hours of dexamethasone treatment (I/Fig. 3), suggesting 
that dexamethasone induces a rapid downregulation by regulating mRNA production or stability 
directly. On the other hand, BRUCE protein level was reduced more slowly and showed no recovery in 
24 hours (I/Fig. 3). BRUCE is known to be regulated by the proteasomal degradation pathway (Qiu et 
al., 2004) suggesting that dexamethasone may affect BRUCE protein level by directing it to the 
proteasome. 
 
5 RESULTS AND DISCUSSION 
5.1 Stress and neuroinflammation decrease NPC survival and maintenance 
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5.1.2 Activated microglia produce IFN that decreases NPC viability 
Activation of microglia is a hallmark of neuroinflammation and can be experimentally induced by LPS, 
a component of bacterial cell wall that is recognized by microglial cells (Bauman et al., 2009). Microglia 
may induce cell death in brain cells by producing inflammatory factors and neurotoxins. To study, 
whether neuroinflammation affects NPCs, LPS was used for microglial activation in a cell culture 
system. LPS stimulation for 24 hours (500 ng/ml) increased the production of an inflammatory 
mediator IFN in microglial culture almost 10-fold (II/Fig. 7). This further resulted in decreased NPC 
viability after NPC treatment with microglia-conditioned medium (II/Fig. 7). However, LPS itself in 
different concentrations (10-500 ng/ml) did not affect NPC survival (II/Fig. 7). The effect of 
microglia-conditioned medium on NPC viability was rescued by neutralization of IFN with 0.25 
μg/ml anti-IFN blocking antibodies (II/Fig. 7), indicating that microglia mediates its effects on NPCs 
via IFN secretion. These results demonstrate that neuroinflammation exerts a negative impact on 
NPCs. 
5.2.1 IFN reduces NPC proliferation 
Cytokines are intercellular signaling molecules secreted by various cell types that activate intracellular 
signaling cascades through binding of cell membrane receptors. IFN is an inflammatory cytokine that 
propagates inflammation by activating IFNRs on the cell membrane. By immunochemistry, we 
observed that IFNRs are present in the embryonic neuroepithelium and in NPCs (II/Fig. 1), and 
further studied the influence of exogenous IFN on NPCs in the cell culture. IFNs signal through 
JAK/STAT pathway. In NPCs, 100 ng/ml IFN was shown to increase phosphorylation of Stat1 after 
30 minutes and to induce its translocation into the nucleus, shown by western blotting and 
immunostaining (II/Fig. 2). Being active in NPCs, IFN signaling decreased the total number of 
Nestin-positive NPCs and reduced the amount of BrdU-positive cells (II/Fig. 2 and 3). Furthermore, 
IFN decreased the number of Ki67-positive NPCs as well as the formation of secondary neurospheres 
(II/Fig. 2 and 3). Moreover, cell cycle analysis revealed that IFN decreased the amount of NPCs in S 
phase and increased those in G0 phase.  
The effect of IFN on NPC proliferation was independent of cell cycle regulators Cyclin D1 or p53Kip2 
since their expression levels were not changed by IFN (II/Fig. 3). Especially, we detected no changes 
in NPC proliferation or survival during p53Kip2 inhibition by siRNA (II/Fig. 3). In addition, cell viability 
was decreased by IFN also in p53Kip2-deficient mouse embryonic fibroblasts (II/Fig. 3), indicating that 
IFN affects cell viability independently of p53Kip2. However, the IFN-mediated decrease in NPC 
proliferation was induced by activation of a CKI p21Cip1 (II/Fig. 3). Downregulation of p21Cip1 with 
specific siRNA rescued the IFN-induced effect on NPC proliferation (II/Fig. 3). p21Cip1 has been 
reported to mediate IFN-induced growth inhibition also in cancer cells (Gooch et al., 2000). 
Moreover, studies of p21Cip1 knockout mice reveal a role for p21Cip1 to inhibit neural progenitor 
proliferation in adults (Kippin et al., 2005; Pechnick et al., 2008).  
Taken together, IFN negatively regulates NPC proliferation and maintenance by activating p21Cip1, 
independent of its upstream regulator p53Kip2 but possibly also by inducing cell cycle exit. NPCs may 
exist as quiescent cells in the adult brain and maintain their ability to self-renew and differentiate. After 
5.2 Cytokine signaling decreases NPC proliferation and affects NPC cell fate 
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brain injury, they are recruited back into the cell cycle to facilitate neurogenesis. Inflammatory 
mediators, like chemokines, have been shown to inhibit proliferation and to induce quiescence of 
human NPCs (Krathwohl and Kaiser, 2004). Thus, IFN may also induce quiescence and promote 
NPC maintenance in some circumstances. In contrast to negative effects of IFN on NPC proliferation 
presented here, it has been shown to promote embryonic NPC proliferation (Li et al., 2010). On the 
other hand, Li et al. (2010) also showed that endogenous IFN inhibits neurogenesis in the non-
inflammatory brain. IFN is usually secreted by immune cells in response to immune activation. 
However, low levels of IFN can be produced also by non-immune cells, like cerebrovascular 
endothelial cells (Wei et al., 2000). Thus, IFN may be important in facilitating niche-specific survival 
signals in non-inflammatory brain but may reduce NPC survival in inflammatory conditions. IFN may 
hence regulate NPC behavior by different ways in different conditions and depending on the exact cell 
population or the cytokine concentration.  
5.2.2 IFN decreases NPC survival and induces cell death 
Reduced cell proliferation may be a consequence of cell death or cell cycle exit due to quiescence or 
differentiation. IFN has been demonstrated to induce neuronal cell death (Jeohn et al., 2000; Sohn et 
al., 2007). Thus, we studied in more detail the mechanisms of IFN on NPC behavior. Already a 
concentration of 1 ng/ml for 48 hours decreased NPC viability in MTT assay (II/Fig. 2). In addition, 
staining of fragmented nuclei with TUNEL or propidium iodide revealed that IFN induces NPC cell 
death (II/Fig. 4). To study cell death mechanism in IFN-treated NPCs, we addressed the expression 
of different proapoptotic proteins. The results indicated that IFN-induced cell death in NPCs involves 
cleavage of caspase-3 as well as poly-ADP ribose polymerase (PARP) (II/Fig. 4), a protein required for 
DNA repair. PARP can be cleaved and inhibited by caspases, which may contribute to inability to 
repair the damaged DNA and finally lead to apoptosis.  
In our further studies, we observed that IFN upregulates the proapoptotic protein PUMA, while it has 
no effect on the expression of other Bcl-2 family proteins, including Bcl-XL and Bax (II/Fig. 6). 
Moreover, IFN-mediated cell death assayed by TUNEL staining was rescued by treating NPCs with a 
non-specific caspase inhibitor, boc-aspartyl(OMe)-fluoro-methylketone (BAF) (II/Fig. 4). These results 
propose that IFN mediates NPC cell death through apoptosis. In line with this, cytochrome c released 
in the cytoplasm was detected in IFN-treated cells further suggesting that IFN induces mitochondrial 
cell death pathway. 
5.2.3 BMPs decrease NPC proliferation and induce their differentiation into astrocytes 
During the embryonic development BMPs are essential cytokines that regulate various cell fates in the 
nervous system. We detected expression of BMP2 and BMP4 as well as their BMP type I receptors 
BMPRIA and BMPRIB, and antagonist Noggin in NPCs in vitro (III/Fig. 6). Furthermore, BMP2 
concomitantly with BMP type I receptors was expressed in the embryonic neuroepithelium, while 
BMP4 expression was not detected in vivo (III/Fig. 6). Stimulation of NPCs with 25 ng/ml of 
exogenous BMP induced Smad1/5/8 phosphorylation (III/Fig. 4) and resulted in decreased number of 
BrdU- and Ki67-positive cells (III/Fig. 4 and data not shown). Moreover, BMP signaling led to 
decreased Cyclin D1 expression that is known to be essential in NPC proliferation (Figure 14; 
Sundberg et al., 2006). BMPs are known to regulate astrocytic cell fate in neuronal progenitor 
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populations (Mehler et al., 1995; Gross et al., 1996; Mabie et al., 1999), so we addressed the effect of 
BMPs on NPC differentiation. In line with previous observations, we detected increase in the amount 
of GFAP-positive astrocytes by BMP2 and BMP4 with no signs of increased β-tubulin or CNPase-
positive neuroblast or oligodendroglia populations, respectively (III/Fig. 5). 
                                
Figure 14. Immunoblot of NPCs. 25 ng/ml of BMP4 decreases Cyclin D1 protein expression. Two forms of Cyclin D1 are shown as 36 kDa and 30-31 kDa bands. β-actin was used as a loading control. 
Inflammatory conditions negatively affected NPC viability, which emphasizes the significance of 
protection of NPCs after neuronal injury to promote their maintenance and recruitment in these 
circumstances. To find potent protective factors, we studied a plethora of neurotrophic factors, 
cytokines, chemokines and immunosuppressive drugs, including BDNF, GDNF, IL-6, IL-10, type I 
IFNs, granulocyte macrophage colony-stimulating factor (GM-CSF), TGFβ, indometacin, minocycline 
and forskolin. None of these factors were able to protect NPC survival against IFN (II/Fig. 5).  
Neuropeptides are protective factors against neurotoxicity in neurons. Hence we studied a 
neuropeptide PACAP in neuroinflammatory conditions. The results revealed that PACAP protects 
NPCs since it rescued IFN-induced effect on cell viability (II/Fig. 5). However, it did not block IFN-
induced Stat1 phosphorylation (II/Fig. 6). PACAP has been shown to inhibit apoptosis and caspase-3 
activation (Vaudry et al., 2003). Expression studies of apoptotic proteins revealed that PACAP inhibits 
pro-apoptotic protein PUMA and cleavage of caspase-3, which were both increased by IFN (II/Fig. 
6). Moreover, PACAP induced phosphorylation and inactivation of a pro-apoptotic protein Bad but it 
did not affect other anti- or pro-apoptotic proteins studied, including Bcl-XL and Bax (II/Fig. 6). 
PACAP acts through PAC1 receptor that is expressed in the developing neuroepithelium (Waschek et 
al., 1998). In neuroepithelial cells, PACAP can activate intracellular protein kinase (PK) pathways, 
including PKA and PKC via the PAC1 (Zhou et al., 2001a). PACAP has been shown to protect NSC 
survival independent of PKA-signaling but to mediate NSC self-renewal and differentiation via PKA 
(Ohta et al., 2006). In addition, PACAP facilitates NSC differentiation through PKC-signaling 
(Watanabe et al., 2006). We hence studied if PACAP acts through protein kinase pathways to mediate 
NPC survival. Inhibition of PKC pathway with a specific antagonist, Gö6976, decreased the survival 
effect of PACAP during IFN treatment, while blocking of PKA-signaling with an inhibitor H89 did 
not (II/Fig. 6). These results indicate that PKC signaling is involved in PACAP-mediated cell survival 
in NPCs. 
PACAP is known to improve NSC proliferation in the adult brain (Mercer et al., 2004; Ohta et al., 
2006). Hence, we studied the effect of PACAP also on NPC proliferation. We observed increase in cell 
proliferation by PACAP but it was not able to rescue the decreased cell proliferation induced by IFN 
(II/Fig. 6). Thus, PACAP serves as a protective factor only against IFN-mediated NPC cell death. As 
shown above, microglial cells produce IFN that reduces NPC viability. Microglia mediates the brain 
5.3 PACAP is able to rescue the decreased NPC survival in neuroinflammatory 
conditions  
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immune function, which is upregulated in many neurodegenerative diseases. Recently, microglia have 
been shown to promote neurogenesis after immune challenge and this effect was dependent on another 
cytokine than IFN (Battista et al., 2006). This suggests that microglia may exert different functions in 
the brain depending on the secreted factors. NPCs themselves can protect against brain inflammation 
(Einstein et al., 2003; Pluchino et al., 2005) and may promote neurogenesis in the pathological brain. 
Thus, it is important to protect NPCs from negative influences of the immune system. We addressed 
the protective effect of PACAP on NPCs during contact with microglia-secreted factors in conditioned 
medium. In line with results presented above, PACAP was able to protect NPCs also for decreased cell 
viability by microglia-produced IFN (II/Fig. 7). 
We have shown that PACAP is a potential rescue factor against NPC cell death in inflammatory 
situations. PACAP may thus serve as a therapeutic agent for brain inflammation in neurological 
disorders as it has been shown to passage the blood-brain barrier (Dogrukol-Ak et al., 2004). It may 
also be useful in brain stem cell therapies to promote NPC survival. The safety and tolerability of 
PACAP has been studied in several human trials that have revealed adverse side effects after systemic 
administration, including pain and altered hormone secretion (Chiodera et al., 1996; Murck et al., 2007; 
Schytz et al., 2010; Amin et al., 2012). In addition, PACAP shows poor metabolic stability, insufficient 
distribution, low bioavailability and fast blood clearance because of its peptidic nature (Bourgault et al., 
2011). Thus, the pharmacokinetic and pharmacological properties of this natural peptide must be first 
improved to develop a clinically appropriate immunoprotective drug.  
5.4.1 BRUCE is degraded by the ubiquitin-proteasome system in NPCs 
BRUCE is a target of proteasomal degradation and it is shown to be regulated by an ubiquitin ligase 
Nrdp1 in the apoptotic pathway (Qiu et al., 2004). To study more closely the regulation of BRUCE by 
dexamethasone in NPCs, we used a proteasome inhibitor MG132 simultaneously with hormone 
treatment. Inhibition of the proteasome was able to rescue BRUCE expression (I/Fig. 4), indicating 
that dexamethasone induces proteasomal degradation of BRUCE in these cells. Nrdp1 stability is 
regulated by a deubiquitinating enzyme Usp8 (Wu et al., 2004) that was expressed in NPCs and 
upregulated by dexamethasone treatment after 3 hours (I/Fig. 4). Mifepristone inhibited the 
upregulation of Usp8 by dexamethasone (I/Fig. 4) referring to glucocorticoid receptor-mediated 
regulation. However, dexamethasone did not affect Nrdp1 expression (I/Fig. 4). Thus, we studied 
possible interactions between these proteins in NPCs by immunoprecipitation of Nrdp1. The results 
revealed that Usp8 and BRUCE were coimmunoprecipitated with Nrdp1 especially in dexamethasone-
treated NPCs (I/Fig. 4) suggesting that dexamethasone-induced upregulation of Usp8 may be required 
for interaction and possible proteasomal degradation of BRUCE by this system. Moreover, subsequent 
Usp8 overexpression experiments indicated that Usp8 downregulates BRUCE protein and inhibits 
NPC proliferation (I/Fig. 4). In conclusion, BRUCE is a potent target for ubiquitination by Nrdp1 in 
NPCs. Furthermore, dexamethasone may induce BRUCE degradation by regulating the Usp8-Nrdp1 
pathway. Altogether, the data indicates that dexamethasone may regulate BRUCE in different ways at 
the mRNA and protein levels. In addition to proteasomal pathway, BRUCE is regulated by a protease 
cleavage of an IAP antagonist Omi/HtrA2 (Qiu et al., 2005). Hence, it would be interesting to study 
whether other proteolytic pathways also affect BRUCE in NPCs. 
 
 
5.4 Proteolytic pathways in NPCs 
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5.4.2 BMPs regulate HAI-1 and HAI-2 expression 
HAI-1 and HAI-2 are cell surface-associated proteins that regulate proteolytic reactions on the plasma 
membrane by inhibiting various target proteases. The upstream signaling of HAI proteins is, however, 
not known. To search for putative regulators of HAI-1 and HAI-2 we used different growth factors 
known to be essential in stem cell regulation, including Wnt3a, TGFβ and BMP4. BMP4 was found to 
upregulate the expression of HAI-1 and HAI-2 at the mRNA level (III/Fig. 3). As BMP4 forms a 
subgroup with BMP2 in the BMP family and they share the same type I receptors, we asked, whether 
BMP2 also regulates HAI proteins. Indeed, BMP2 upregulated HAI-1 both at the mRNA and protein 
level and increased also HAI-2 mRNA levels (III/Fig. 3). BMPs affect transcription of various target 
genes via Smad or MAPK signaling pathways. One of the target genes of BMPs include a transcription 
factor GATA2 (Dalgin et al., 2007), which is a potent regulator of HAI-1 and HAI-2 gene expression, 
as its binding site is present in the promoter regions of both HAI proteins (Itoh et al., 2001). This 
proposes that GATA2 may mediate BMP-induced increases in HAI-1 and HAI-2 expression and that 
HAI-1 and HAI-2 are regulated at the gene expression level. In conclusion, cell surface protease 
inhibitors HAI-1 and HAI-2 are targets of cytokine signaling in NPCs. 
5.4.3 Serine protease inhibitors HAI-1 and HAI-2 reduce NPC proliferation 
HAI-1 and HAI-2 are transmembrane serine protease inhibitors that are abundantly expressed in 
epithelial tissues (Szabo et al., 2008), and hence we studied their existence at the embryonic and 
postnatal neuroepithelium. Staining with specific antibodies showed expression of these proteins at the 
neurogenic area of the brain and their colocalization in neural progenitor population was indicated with 
Nestin double-expression (III/Fig. 1). Moreover, HAI-1 and HAI-2 expression was detected in 
cultured NPCs with proliferation and progenitor markers Ki67 and Nestin, respectively (III/Fig. 1). 
Closer look of proliferating and differentiated NPCs revealed their differential expression pattern, HAI-
1 expression being constant during differentiation, while HAI-2 expression was downregulated in 
differentiated cells (III/Fig. 1). Since both HAI proteins were present in NPCs, we addressed their 
function in these cells using overexpression constructs of the full-length as well as truncated forms of 
proteins, the latter lacking the transmembrane (TM) domain. Forced expression of HAI-1 and HAI-2 
in NPCs led to decreased amount of Ki67-positive cells (III/Fig. 2). No differences were observed 
between the full-length and TM-lacking isoforms of the proteins, indicating that the extracellular part 
of the proteins, containing the Kunitz domains, is responsible for the effect on proliferation. This 
suggests that inhibition of target proteases via KDs is required for proper NPC division. Subsequently 
to decreased proliferative capacity of NPCs, HAI-1 and HAI-2 overexpression resulted in decreased 
expression of Cyclin D1 (III/Fig. 2) suggesting that they may induce cell cycle arrest or exit in NPCs. 
In addition, overexpression of HAI-1 decreased phosphorylation of ERK1 and -2 (ERK1/2) (III/Fig. 
2), whose activity is known to be essential in maintenance of brain stem cells (Enarsson et al., 2002). 
To study, whether endogenous HAI proteins affect NPC proliferation, we used specific siRNAs to 
downregulate their expression. Reduction of both HAI-1 and HAI-2 levels by siRNA increased the 
number of BrdU-positive NPCs (III/Fig. 2). Furthermore, inhibition of HAI-1 with a specific 
monoclonal antibody, MG2, led to a similar result (III/Fig. 2). Collectively, these findings suggest that 
HAI proteins could inhibit NPC proliferation by regulating important cell cycle proteins and by 
affecting intracellular signaling pathways subsequently to protease inhibition. 
As indicated above, HAI proteins and BMP2 and BMP4 have similar impact on NPC proliferation and 
BMPs were shown to increase HAI expression. This raised a possibility that HAI proteins mediate the 
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effects of BMPs on NPC proliferation. To prove this hypothesis, we simultaneously treated NPCs with 
BMP4 and HAI-1 or HAI-2 siRNA. Inhibition of HAI-1 and HAI-2 separately was able to partially 
rescue the amount of BrdU-positive dividing cells that was decreased by BMP (III/Fig. 4). These 
results show that BMP2 and BMP4 at least partially mediate their effects on cell proliferation via HAI 
proteins, which describes a novel signaling mechanism where cytokine signaling may regulate cellular 
behavior via transmembrane proteins other than cell adhesion molecules. 
5.4.4 HAI-1 induces astrogliogenesis and regulates NPCs in vivo 
BMPs were shown to upregulate HAI expression and to induce astroglial differentiation of NPCs. 
Thus, we studied if HAI proteins are also involved in regulation of NPC differentiation. 
Overexpression of HAI-1 resulted in increased number of GFAP-positive astroglia in culture (III/Fig. 
5). However, the amount of βIII-tubulin-positive neuroblasts or CNPase-positive oligodendrocytes was 
not affected (III/Fig. 5). In contrast to HAI-1, HAI-2 overexpression did not have a significant effect 
on NPC differentiation (III/Fig. 5). To further study if HAI-1 is responsible for BMP-induced effect 
on increased astrogliogenesis, we treated BMP2-stimulated cells simultaneously with HAI-1 siRNA. 
The results indicated that blocking of HAI-1 expression inhibits BMP-induced astroglial formation in 
culture (III/Fig. 5), demonstrating that at least BMP2 regulates astrogliogenesis concomitantly with 
HAI-1. 
HAI-1 was shown to be a more potent regulator of NPCs, possibly due to partial redundancy of HAI-2 
to HAI-1 that is also suggested before (Szabo et al., 2008; 2009). Thus, we focused on HAI-1 in order 
to address the in vivo effects of these protease inhibitors in neural progenitor cells. Since HAI-1 
knockout mice are embryonic lethal already during the early developmental stage and HAI-1 
heterozygotes display normal physiology (Tanaka et al., 2005), we decided to use in utero electroporation 
method to achieve HAI-1 overexpression in the brains of older embryos. HAI-1 expression vector 
under the pCAG promoter together with a control GFP vector was introduced into the embryonic E14 
or E17 mouse brain to study the proliferation and differentiation of targeted cells, respectively. The 
achieved results confirmed the in vitro effects of HAI-1 in NPCs, including decreased amount of Ki67-
positive cells in the embryonic E15-old neuroepithelium (III/Fig. 7) and increased number of GFAP-
positive astroglia in P1 brains (III/Fig. 8). Taken together, these results show that HAI-1 is an 
important regulator of proliferation and astroglial cell fate in NPCs. 
5.4.5 Potent targets of HAI proteins in NPCs 
HAI-1 and HAI-2 share several common target proteases. They were originally identified as potent 
inhibitors of HGFA (Kawaguchi et al., 1997; Shimomura et al., 1997) that exerts its effects on cell 
behavior and tissue regeneration through activation of HGF zymogen (Shimomura et al., 1992). We 
thus studied the expression and/or function of HGFA and HGF in NPCs as potent targets of HAI 
protein inhibition. Both HGF and HGFA were present in proliferating NPCs (III/Suppl.Fig. 1). 
However, HAI overexpression did not affect HGFA expression levels (III/Suppl.Fig. 1) proposing that 
it is not a target for HAI inhibition. Moreover, HGF receptor c-Met was nearly absent in NPCs 
(III/Suppl.Fig. 1). To further elucidate the possible role of HGF in NPCs, we studied the effect of c-
Met inhibitor SU11274 and exogenous HGF on NPC proliferation. Neither of these factors affected 
the amount of BrdU-positive cells in culture (III/Suppl.Fig. 1). To exclude the possibility that HAI 
proteins may inhibit HGF function, we used HAI siRNAs concurrently with exogenous HGF in the 
study of NPC proliferation. We observed no changes in NPC proliferation by HGF (III/Suppl.Fig. 1). 
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These results indicate that HGF signaling is not involved in the regulation of NPC proliferation in the 
present conditions and that HAI proteins do not facilitate their effects on NPC cell division through 
HGFA/HGF. As HGF is known to be activated by HGFA in injured tissue (Miyazawa et al., 1996), 
the role of HGF signaling would be interesting to assess in the situation of brain injury or 
inflammation. On the other hand, HGF has been shown to affect neuronal maturation (Korhonen et 
al., 2000) suggesting that it might be involved in NPC differentiation and/or migration. This, however, 
insists further studies. 
Lack of HGF signaling in NPCs in the present study proposes that HAI proteins may have other target 
protease(s) in these cells. Matriptase is a membrane-associated serine protease that is abundantly 
coexpressed with HAI-1 and HAI-2 in epithelial tissues (Szabo et al., 2008). Matriptase is involved in 
neural tube closure during the brain development but it is regulated by a complex manner requiring 
both HAI-1 and HAI-2 inhibitors as well as hepsin and prostasin as activators (Szabo et al., 2009; 
Camerer et a., 2010). This suggests that matriptase may serve as a potent target for HAI proteins in 
NPCs and could be involved in NPC proliferation. We detected expression of matriptase especially in 
proliferating NPCs and the expression was localized to the same cells with HAI proteins (Figure 15A-
B). Furthermore, matriptase expression was downregulated after forced expression of HAI-1 and HAI-
2 (Figure 15C). These expression studies suggest that matriptase may be a target of HAI protein 
inhibition in NPCs. Moreover, matriptase could regulate NPC proliferation and/or differentiation but 
this requires further analysis. 
                       
Figure 15. Expression of matriptase (MTP) in NPCs. A. MTP is expressed in proliferating (P) NPCs as a complexed form with HAI-1, shown as 95 kDa and 110 kDa bands. MTP expression declines during NPC 
differentiation (D). β-actin was used as a loading control. B. Confocal microscopy shows colocalization of MTP with HAI-1 and HAI-2 in dissociated NPCs. Scale bar, 20 µm. C. MTP expression decreases after HAI-1 and HAI-2 
overexpression. β-actin was used as a loading control. Quantification of 95 kDa and 110 kDa bands is shown on the right. Values are means ±SEM, n=3. ** p < 0.01, * p< 0.05 by Student's t-test. 
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In this thesis work I have aimed to study NPCs and how they are affected by brain inflammation and 
proteolytic pathways. NPC development is regulated by diverse signals through interactions with other 
cells in their local environment. The knowledge of the mechanisms governing the maintenance and 
differentiation of NPCs is relevant in the situations of brain injury and disease, where neurons 
degenerate and NPCs could serve as a reservoir for cell replacement. Neurodegenerative diseases and 
brain trauma are associated with inflammation that can have an impact on cell survival and behavior. 
The precise outcome of brain inflammation whether friend or foe for brain regeneration is hard to 
control or predict.   
The thesis work unveils an important interplay between neural progenitor cells and brain microglia that 
could play a role in neuroinflammation and in brain diseases. This interaction involves the cytokine 
IFN produced from microglia with unfavorable influence on NPC proliferation and survival. IFN 
was found to inhibit NPC proliferation via effects on the cell cycle machinery and to decrease cell 
viability by inducing cell death signals in the NPCs. The effects on NPC cell viability were counteracted 
by the neuropeptide PACAP that also decreased microglial secretion of inflammatory mediators. 
PACAP could be used as a potential factor in treatment of brain inflammation and in 
neurodegenerative diseases, in which activated microglia contribute to disease progression. However, it 
will be important to study the potential role of PACAP in the in vivo setting of neuroinflammation and 
brain diseases. In addition, the use of PACAP as a clinically competent drug would require 
modifications to improve pharmacological properties of this natural peptide. 
Cell proliferation is linked to the proper activity of the UPS through regulation of key proteins involved 
in the cell cycle. We observed that the expression levels of BRUCE are negatively regulated by the 
synthetic glucocorticoid hormone dexamethasone, possibly via the UPS. BRUCE is a ubiquitin-
conjugating enzyme and was crucial for the regulation of NPC division. BRUCE could mediate its 
effect on cell proliferation by targeting cell cycle regulators or the components of the midbody ring 
involved in cytokinesis. The precise targets for BRUCE in NPCs and how it influences NPC 
development needs to be studied more in the future. 
The present work also unravels a novel signaling system in the NPCs to guide cell development and 
differentiation. The BMP family of cytokines are essential factors in many developmental pathways. We 
observed that BMPs regulate the cell membrane-anchored protease inhibitors HAI-1 and HAI-2 
expressed by the NPCs and also control cell proliferation and fate. The effects of BMPs were observed 
both in cell cultures and in developing neuroepithelium in vivo and were found to be age-dependent. At 
an earlier developmental stage the BMPs reduced proliferation and at later stages the BMPs induced 
differentiation of NPCs into astrocytes. The precise mechanisms underlying these cell responses remain 
to be studied further, but as bona fide protease inhibitors, HAI-1 and HAI-2 may influence several 
signaling cascades important for cell fate decision and cell proliferation. However, the target protease(s) 
in the NPCs regulated by the HAI proteins warrant more studies. The HAI proteins and their 
downstream proteases could serve as therapeutic targets to modulate proteolytic cascades in the NPCs, 
and provide a valuable tool for stem cell therapies in various brain diseases. 
Overall, the regulation of NPCs is important in conditions like stress and inflammation that affect 
neurogenesis. Chronic stress and inflammation may result in various neurological diseases and 
disorders or, vice versa, they may occur secondary to pathogenesis and brain trauma. NPCs are also a 
potent target for stem cell therapy to facilitate neurogenesis and brain recovery in disease.  
6 CONCLUSIONS AND FUTURE PROSPECTS 
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Figure 16. Conclusions. Stress is associated with decreased neurogenesis, and it may affect the immune system by changing glucocorticoid hormone (GH) levels. A synthetic GH, dexamethasone, was shown to inhibit the expression of protein BRUCE that is required for proper neural progenitor cell (NPC) proliferation. Brain damage can activate the immune system leading to neuroinflammation that is involved in the pathogenesis of brain diseases and disorders. During neuroinflammation, microglia produce proinflammatory cytokines such as interferon(IFN)- that reduces NPC proliferation and survival. Neuropeptide PACAP has a dual role in promoting NPC survival by inhibiting microglial secretion of IFN and by counteracting the IFN-induced cell death. Because of its protective role, PACAP could be useful in treatment of brain inflammation and disease, as well as in brain stem cell therapy.  In addition to proinflammatory cytokines, other cytokines, such as bone morphogenetic proteins (BMPs), regulate NPC behaviour. BMP2 and BMP4 increase HAI-1 and HAI-2 protein expression in developing NPCs resulting in reduced proliferative capacity of these cells. Moreover, HAI-1 mediates the effects of BMP2/4 on NPC differentiation by inducing gliogenesis. Increased NPC proliferation and survival contributes to neurogenesis that is affected in neurological diseases. Stem cell therapies by stimulating the endogenous NPCs or by transplantation of stem cells into the brain could enhance neurogenesis and recovery in brain injury or disease. 
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